PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25637582-0	2015	Interaction of fenoterol stereoisomers with beta2-adrenoceptor-G salpha fusion proteins: antagonist and agonist competition binding.	Fenoterol	15-24	adrenoceptor beta 2	Homo sapiens	44-62
25637582-2	2015	Fenoterol stereoisomers were successfully used to probe ligand-specific activation (functional selectivity) of the beta2-adrenoceptor (beta2AR) (Reinartz et al.	Fenoterol	0-9	adrenoceptor beta 2	Homo sapiens	115-133
25637582-2	2015	Fenoterol stereoisomers were successfully used to probe ligand-specific activation (functional selectivity) of the beta2-adrenoceptor (beta2AR) (Reinartz et al.	Fenoterol	0-9	adrenoceptor beta 2	Homo sapiens	135-142
25637582-4	2015	In the present study, we extended the pharmacological profile of fenoterol stereoisomers using beta2AR-Gsalpha fusion proteins in agonist and antagonist competition binding assays.	Fenoterol	65-74	adrenoceptor beta 2	Homo sapiens	95-102
25637608-3	2015	We previously reported that the beta2-agonist fenoterol, direct activation of protein kinase A (PKA), and exchange factor directly activated by cAMP decrease cigarette smoke extract (CSE)-induced release of neutrophil attractant interleukin-8 (IL-8) from human airway smooth muscle (ASM) cells.	Fenoterol	46-55	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	32-37
25637608-3	2015	We previously reported that the beta2-agonist fenoterol, direct activation of protein kinase A (PKA), and exchange factor directly activated by cAMP decrease cigarette smoke extract (CSE)-induced release of neutrophil attractant interleukin-8 (IL-8) from human airway smooth muscle (ASM) cells.	Fenoterol	46-55	C-X-C motif chemokine ligand 8	Homo sapiens	229-242
25637608-10	2015	The modulatory role of AKAP-PKA interactions in the anti-inflammatory effects of fenoterol in ASM cells and the decrease in expression of AKAP5 and AKAP12 in response to cigarette smoke and in lungs of patients with COPD suggest that cigarette smoke-induced changes in AKAP5 and AKAP12 in patients with COPD may affect efficacy of pharmacotherapy.	Fenoterol	81-90	A-kinase anchoring protein 1	Homo sapiens	23-27
26634602-2	2015	beta;2-agonists can be broadly classified according to their duration of action: short-acting beta2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics halflives between 2 and 6 h and long-acting beta2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment.	Fenoterol	155-164	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-6
26634602-2	2015	beta;2-agonists can be broadly classified according to their duration of action: short-acting beta2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics halflives between 2 and 6 h and long-acting beta2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment.	Fenoterol	155-164	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	94-99
25324048-7	2015	Combining these, in the double mutant beta2-H296K-K305D, reduced salmeterol"s affinity by 275-fold, to within 4-fold of that of the beta1-adrenoceptor, without affecting the affinity or selectivity of other beta2-agonists (salbutamol, formoterol, fenoterol, clenbuterol, or adrenaline).	Fenoterol	247-256	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-43
25342094-0	2015	Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the beta2-adrenoceptor.	Fenoterol	33-42	adrenoceptor beta 2	Homo sapiens	101-119
25342094-8	2015	Ligand bias was calculated using an operational model of agonism and revealed that the fenoterol scaffold constitutes a promising lead structure for the development of Gs-biased beta2AR agonists.	Fenoterol	87-96	adrenoceptor beta 2	Homo sapiens	178-185
24785981-4	2014	This visual color discrepancy has been used to intuitively and conveniently differentiate the phenolic group beta2-agonists, such as ractopamine, isoxsuprine, ritodrine, and fenoterol.	Fenoterol	174-183	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	109-114
24182991-3	2014	We aimed to assess the association of the effect of fenoterol (beta2-AR agonist) on IL-4-driven and budesonide-induced IgE synthesis with genetic variants of beta2-AR.	Fenoterol	52-61	adrenoceptor beta 2	Homo sapiens	63-71
24182991-3	2014	We aimed to assess the association of the effect of fenoterol (beta2-AR agonist) on IL-4-driven and budesonide-induced IgE synthesis with genetic variants of beta2-AR.	Fenoterol	52-61	interleukin 4	Homo sapiens	84-88
24182991-3	2014	We aimed to assess the association of the effect of fenoterol (beta2-AR agonist) on IL-4-driven and budesonide-induced IgE synthesis with genetic variants of beta2-AR.	Fenoterol	52-61	immunoglobulin heavy constant epsilon	Homo sapiens	119-122
24182991-3	2014	We aimed to assess the association of the effect of fenoterol (beta2-AR agonist) on IL-4-driven and budesonide-induced IgE synthesis with genetic variants of beta2-AR.	Fenoterol	52-61	adrenoceptor beta 2	Homo sapiens	158-166
24182991-7	2014	RESULTS: In -47 T/T and -20 T/T patients, incubation with fenoterol resulted in decreased IgE production, whereas in -47 C/T and -47 C/C as well as in -20 C/T and -20 C/C individuals, it was enhanced.	Fenoterol	58-67	immunoglobulin heavy constant epsilon	Homo sapiens	90-93
25360795-5	2014	After preparation, bronchial rings and primary cultures of bronchial epithelial cells were incubated with fenoterol (0.1 microM, 15 hours, 37  C), a beta2-agonist with high intrinsic efficacy.	Fenoterol	106-115	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	149-154
25360795-7	2014	RESULTS: Compared to paired controls, fenoterol-sensitization was abolished by inhibition/blockage of the Wnt/beta-catenin signaling, especially the cell-surface LRP5/6 co-receptors or Fzd receptors (1 microM SFRP1 or 1 microM DKK1) and the nuclear recruitment of TCF/LEF transcriptions factors (0.3 microM FH535).	Fenoterol	38-47	catenin beta 1	Homo sapiens	110-122
25360795-7	2014	RESULTS: Compared to paired controls, fenoterol-sensitization was abolished by inhibition/blockage of the Wnt/beta-catenin signaling, especially the cell-surface LRP5/6 co-receptors or Fzd receptors (1 microM SFRP1 or 1 microM DKK1) and the nuclear recruitment of TCF/LEF transcriptions factors (0.3 microM FH535).	Fenoterol	38-47	LDL receptor related protein 5	Homo sapiens	162-168
25360795-7	2014	RESULTS: Compared to paired controls, fenoterol-sensitization was abolished by inhibition/blockage of the Wnt/beta-catenin signaling, especially the cell-surface LRP5/6 co-receptors or Fzd receptors (1 microM SFRP1 or 1 microM DKK1) and the nuclear recruitment of TCF/LEF transcriptions factors (0.3 microM FH535).	Fenoterol	38-47	secreted frizzled related protein 1	Homo sapiens	209-214
25360795-7	2014	RESULTS: Compared to paired controls, fenoterol-sensitization was abolished by inhibition/blockage of the Wnt/beta-catenin signaling, especially the cell-surface LRP5/6 co-receptors or Fzd receptors (1 microM SFRP1 or 1 microM DKK1) and the nuclear recruitment of TCF/LEF transcriptions factors (0.3 microM FH535).	Fenoterol	38-47	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	227-231
25360795-10	2014	CONCLUSIONS: Collectively, our pharmacological investigations indicate that fenoterol-sensitization is modulated by the inhibition/blockage of canonical Wnt/beta-catenin pathway, suggesting a phenomenon of biased agonism in connection with the beta2-adrenoceptor stimulation.	Fenoterol	76-85	catenin beta 1	Homo sapiens	157-169
25360795-10	2014	CONCLUSIONS: Collectively, our pharmacological investigations indicate that fenoterol-sensitization is modulated by the inhibition/blockage of canonical Wnt/beta-catenin pathway, suggesting a phenomenon of biased agonism in connection with the beta2-adrenoceptor stimulation.	Fenoterol	76-85	adrenoceptor beta 2	Homo sapiens	244-262
24732071-1	2014	OBJECTIVE: The aim of this study was to investigate whether the use of fenoterol, a beta2-adrenergic agonist, was associated with multiple sclerosis (MS) risk by conducting a total population-based case-control study in Taiwan.	Fenoterol	71-80	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	84-89
24633512-3	2014	Using His-tagged beta2-adrenoceptor (beta2-AR) as a probe, we developed a new mathematical model to elucidate the interactions between the receptor and five ligands (methoxyphenamine, terbutaline, salbutamol, tulobuterol and fenoterol).	Fenoterol	225-234	adrenoceptor beta 2	Homo sapiens	17-35
24633512-3	2014	Using His-tagged beta2-adrenoceptor (beta2-AR) as a probe, we developed a new mathematical model to elucidate the interactions between the receptor and five ligands (methoxyphenamine, terbutaline, salbutamol, tulobuterol and fenoterol).	Fenoterol	225-234	adrenoceptor beta 2	Homo sapiens	37-45
22434858-6	2012	The beta(2)-AR agonists tested in this study have considerably higher affinity for the agonist conformation of the receptor, and K(i) values determined for fenoterol analogs model much better the cAMP activity of the beta(2)-AR elicited by these ligands.	Fenoterol	156-165	adrenoceptor beta 2	Homo sapiens	4-14
24441217-1	2014	Fenoterol and its derivatives are selective beta2-adrenergic receptor (beta2-AR) agonists whose stereoselective biological activities have been extensively investigated in the past decade; a complete stereochemical characterization of fenoterol derivatives is therefore crucial for a better understanding of the effects of stereochemistry on beta2-AR binding.	Fenoterol	0-9	adrenoceptor beta 2	Homo sapiens	44-69
24441217-1	2014	Fenoterol and its derivatives are selective beta2-adrenergic receptor (beta2-AR) agonists whose stereoselective biological activities have been extensively investigated in the past decade; a complete stereochemical characterization of fenoterol derivatives is therefore crucial for a better understanding of the effects of stereochemistry on beta2-AR binding.	Fenoterol	0-9	adrenoceptor beta 2	Homo sapiens	71-79
24441217-1	2014	Fenoterol and its derivatives are selective beta2-adrenergic receptor (beta2-AR) agonists whose stereoselective biological activities have been extensively investigated in the past decade; a complete stereochemical characterization of fenoterol derivatives is therefore crucial for a better understanding of the effects of stereochemistry on beta2-AR binding.	Fenoterol	0-9	adrenoceptor beta 2	Homo sapiens	342-350
24441217-1	2014	Fenoterol and its derivatives are selective beta2-adrenergic receptor (beta2-AR) agonists whose stereoselective biological activities have been extensively investigated in the past decade; a complete stereochemical characterization of fenoterol derivatives is therefore crucial for a better understanding of the effects of stereochemistry on beta2-AR binding.	Fenoterol	235-244	adrenoceptor beta 2	Homo sapiens	71-79
24121469-1	2013	Fenoterol, a fast-acting beta2-adrenergic agonist, is used in the therapy of obstructive pulmonary diseases and for the inhibition of premature labour obstetrics.	Fenoterol	0-9	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	25-30
24043542-0	2013	Molecular interactions between fenoterol stereoisomers and derivatives and the beta2-adrenergic receptor binding site studied by docking and molecular dynamics simulations.	Fenoterol	31-40	adrenoceptor beta 2	Homo sapiens	79-104
24043542-2	2013	In the present study stereoisomers of fenoterol and some of its derivatives (N = 94 molecules) were used as molecular probes to identify differences in stereo-recognition interactions between beta2-AR and structurally similar agonists.	Fenoterol	38-47	adrenoceptor beta 2	Homo sapiens	192-200
24043542-3	2013	The present study aimed at determining the 3D molecular models of the fenoterol derivative-beta2-AR complexes.	Fenoterol	70-79	adrenoceptor beta 2	Homo sapiens	91-99
24043542-9	2013	Furthermore, the molecular dynamics simulations were used to study the molecular mechanism of interaction between ligands ((R,R")- and (S,S")-fenoterol) and beta2-AR.	Fenoterol	135-151	adrenoceptor beta 2	Homo sapiens	157-165
23348973-4	2013	Traditional inhaled short-acting beta2-agonists albuterol, fenoterol, and terbutaline provide rapid as-needed symptom relief and short-term prophylactic protection against bronchoconstriction induced by exercise or other stimuli.	Fenoterol	59-68	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	33-38
22776956-1	2012	Inhibition of cell proliferation by fenoterol and fenoterol derivatives in 1321N1 astrocytoma cells is consistent with beta(2)-adrenergic receptor (beta(2)-AR) stimulation.	Fenoterol	36-45	adrenoceptor beta 2	Homo sapiens	119-146
22776956-1	2012	Inhibition of cell proliferation by fenoterol and fenoterol derivatives in 1321N1 astrocytoma cells is consistent with beta(2)-adrenergic receptor (beta(2)-AR) stimulation.	Fenoterol	36-45	adrenoceptor beta 2	Homo sapiens	148-158
22776956-1	2012	Inhibition of cell proliferation by fenoterol and fenoterol derivatives in 1321N1 astrocytoma cells is consistent with beta(2)-adrenergic receptor (beta(2)-AR) stimulation.	Fenoterol	50-59	adrenoceptor beta 2	Homo sapiens	119-146
22776956-1	2012	Inhibition of cell proliferation by fenoterol and fenoterol derivatives in 1321N1 astrocytoma cells is consistent with beta(2)-adrenergic receptor (beta(2)-AR) stimulation.	Fenoterol	50-59	adrenoceptor beta 2	Homo sapiens	148-158
22760074-0	2012	Fenoterol functionally activates the beta3-adrenoceptor in human urinary bladder, comparison with rat and mouse: implications for drug discovery.	Fenoterol	0-9	adrenoceptor beta 3	Homo sapiens	37-55
22760074-1	2012	Fenoterol has been reported to be a potent and selective beta(2)-adrenoceptor agonist and is currently used clinically to treat asthma.	Fenoterol	0-9	adrenoceptor beta 2	Homo sapiens	57-77
22760074-5	2012	Fenoterol was added cumulatively in the presence of the beta(2)-adrenoceptor antagonist ICI118551 or the beta(3)-adrenoceptor antagonist L-748337.	Fenoterol	0-9	adrenoceptor beta 2	Homo sapiens	56-76
22760074-5	2012	Fenoterol was added cumulatively in the presence of the beta(2)-adrenoceptor antagonist ICI118551 or the beta(3)-adrenoceptor antagonist L-748337.	Fenoterol	0-9	adrenoceptor beta 3	Homo sapiens	105-125
22760074-9	2012	In rat bladder ICI118551 (30 nM) was without effect, while L-748,337 (10 muM) inhibited the response to fenoterol with a pA(2) of 5.40.	Fenoterol	104-113	latexin	Homo sapiens	73-76
24615679-4	2014	The method has been successfully tested on the beta2-adrenergic receptor (beta2-AR) binding the four fenoterol stereoisomers by both metadynamics simulations and replica-exchange MD.	Fenoterol	101-110	adrenoceptor beta 2	Homo sapiens	47-72
24615679-4	2014	The method has been successfully tested on the beta2-adrenergic receptor (beta2-AR) binding the four fenoterol stereoisomers by both metadynamics simulations and replica-exchange MD.	Fenoterol	101-110	adrenoceptor beta 2	Homo sapiens	74-82
24326276-0	2014	Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the beta2-adrenergic receptor.	Fenoterol	40-49	adrenoceptor beta 2	Homo sapiens	113-138
24326276-6	2014	The CoMFA model of the agonist-stabilized beta2-AR suggests that the binding of the fenoterol analogs to an agonist-stabilized conformation of the beta2-AR is governed to a greater extend by steric effects than binding to the [(3)H]-CGP-12177-stabilized conformation(s) in which electrostatic interactions play a more predominate role.	Fenoterol	84-93	adrenoceptor beta 2	Homo sapiens	42-50
24326276-6	2014	The CoMFA model of the agonist-stabilized beta2-AR suggests that the binding of the fenoterol analogs to an agonist-stabilized conformation of the beta2-AR is governed to a greater extend by steric effects than binding to the [(3)H]-CGP-12177-stabilized conformation(s) in which electrostatic interactions play a more predominate role.	Fenoterol	84-93	adrenoceptor beta 2	Homo sapiens	147-155
22434858-6	2012	The beta(2)-AR agonists tested in this study have considerably higher affinity for the agonist conformation of the receptor, and K(i) values determined for fenoterol analogs model much better the cAMP activity of the beta(2)-AR elicited by these ligands.	Fenoterol	156-165	adrenoceptor beta 2	Homo sapiens	217-227
22390078-2	2011	Recently we revealed the slow developing (for 20-40 min) positive inotropic effect in the mouse atrium which was induced by the specific agonist of the beta2-adrenoceptors (5 mkM fenoterol) and the task of this study involved investigation of the found effect.	Fenoterol	179-188	hemoglobin, beta adult minor chain	Mus musculus	152-157
22328006-1	2012	PURPOSE: A salutary effect of beta(2) adrenergic receptor (AR) agonist, fenoterol has been demonstrated in a rat model of post-myocardial infarction (MI) dilated cardiomyopathy (DCM).	Fenoterol	72-81	adrenoceptor beta 2	Rattus norvegicus	30-57
20888833-4	2011	Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of beta(2) AR agonist, fenoterol, in combination with a beta(1) AR blocker, metoprolol, is more effective than beta(1) AR blocker alone and as effective as beta(1) AR blocker with ACE inhibitor with respect to survival and cardiac remodeling.	Fenoterol	153-162	angiotensin I converting enzyme	Rattus norvegicus	310-313
21365223-7	2011	In case of agonists of beta(2)AR, the (R,R) and (S,S) stereoisomers of fenoterol, the molecular dynamics simulations provided evidence of different binding modes while preserving the same average position of ligands in the binding site.	Fenoterol	71-80	adrenoceptor beta 2	Homo sapiens	23-32
21618615-0	2011	Effect of fenoterol stereochemistry on the beta2 adrenergic receptor system: ligand-directed chiral recognition.	Fenoterol	10-19	adrenoceptor beta 2	Rattus norvegicus	43-68
21320165-0	2011	Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells.	Fenoterol	36-45	C-C motif chemokine ligand 5	Homo sapiens	49-55
21320165-0	2011	Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells.	Fenoterol	36-45	C-X-C motif chemokine ligand 10	Homo sapiens	60-65
21320165-5	2011	However, whether albuterol and fenoterol (two SABAs) have modulatory effects on RANTES and IP-10 expression in bronchial epithelial cells is unknown.	Fenoterol	31-40	C-C motif chemokine ligand 5	Homo sapiens	80-86
21320165-5	2011	However, whether albuterol and fenoterol (two SABAs) have modulatory effects on RANTES and IP-10 expression in bronchial epithelial cells is unknown.	Fenoterol	31-40	C-X-C motif chemokine ligand 10	Homo sapiens	91-96
21320165-10	2011	Albuterol and fenoterol suppressed poly I:C-induced RANTES and IP-10 expression of BEAS-2B cells.	Fenoterol	14-23	C-C motif chemokine ligand 5	Homo sapiens	52-58
21320165-10	2011	Albuterol and fenoterol suppressed poly I:C-induced RANTES and IP-10 expression of BEAS-2B cells.	Fenoterol	14-23	C-X-C motif chemokine ligand 10	Homo sapiens	63-68
21320165-11	2011	ICI-118551 could partly reverse the suppressive effects of albuterol and fenoterol on RANTES and IP-10 expression.	Fenoterol	73-82	C-C motif chemokine ligand 5	Homo sapiens	86-92
21320165-11	2011	ICI-118551 could partly reverse the suppressive effects of albuterol and fenoterol on RANTES and IP-10 expression.	Fenoterol	73-82	C-X-C motif chemokine ligand 10	Homo sapiens	97-102
21320165-16	2011	Albuterol and fenoterol could suppress poly I:C-induced RANTES and IP-10 expression in human bronchial epithelial cells via at least partly the beta2-adrenoreceptor-cAMP and the MAPK pathways, implicating that albuterol and fenoterol could exert anti-inflammatory effect and benefit asthmatic patients by suppressing RANTES and IP-10 expression.	Fenoterol	14-23	C-C motif chemokine ligand 5	Homo sapiens	56-62
21320165-16	2011	Albuterol and fenoterol could suppress poly I:C-induced RANTES and IP-10 expression in human bronchial epithelial cells via at least partly the beta2-adrenoreceptor-cAMP and the MAPK pathways, implicating that albuterol and fenoterol could exert anti-inflammatory effect and benefit asthmatic patients by suppressing RANTES and IP-10 expression.	Fenoterol	14-23	C-X-C motif chemokine ligand 10	Homo sapiens	67-72
21320165-16	2011	Albuterol and fenoterol could suppress poly I:C-induced RANTES and IP-10 expression in human bronchial epithelial cells via at least partly the beta2-adrenoreceptor-cAMP and the MAPK pathways, implicating that albuterol and fenoterol could exert anti-inflammatory effect and benefit asthmatic patients by suppressing RANTES and IP-10 expression.	Fenoterol	14-23	adrenoceptor beta 2	Homo sapiens	144-164
21320165-16	2011	Albuterol and fenoterol could suppress poly I:C-induced RANTES and IP-10 expression in human bronchial epithelial cells via at least partly the beta2-adrenoreceptor-cAMP and the MAPK pathways, implicating that albuterol and fenoterol could exert anti-inflammatory effect and benefit asthmatic patients by suppressing RANTES and IP-10 expression.	Fenoterol	14-23	mitogen-activated protein kinase 1	Homo sapiens	178-182
21320165-16	2011	Albuterol and fenoterol could suppress poly I:C-induced RANTES and IP-10 expression in human bronchial epithelial cells via at least partly the beta2-adrenoreceptor-cAMP and the MAPK pathways, implicating that albuterol and fenoterol could exert anti-inflammatory effect and benefit asthmatic patients by suppressing RANTES and IP-10 expression.	Fenoterol	14-23	C-C motif chemokine ligand 5	Homo sapiens	317-323
21320165-16	2011	Albuterol and fenoterol could suppress poly I:C-induced RANTES and IP-10 expression in human bronchial epithelial cells via at least partly the beta2-adrenoreceptor-cAMP and the MAPK pathways, implicating that albuterol and fenoterol could exert anti-inflammatory effect and benefit asthmatic patients by suppressing RANTES and IP-10 expression.	Fenoterol	14-23	C-X-C motif chemokine ligand 10	Homo sapiens	328-333
22649689-1	2011	The effects of the selective beta(2)-adrenoreceptor agonist (fenoterol) on the functioning of mouse atrial were studied using both tensometry and fluorescent methods.	Fenoterol	61-70	adrenergic receptor, beta 2	Mus musculus	29-51
21618615-2	2011	Fenoterol (FEN) is a beta(2)-AR selective agonist that has two centers of chirality and exists as four stereoisomers.	Fenoterol	0-9	adrenoceptor beta 2	Rattus norvegicus	21-31
21618615-2	2011	Fenoterol (FEN) is a beta(2)-AR selective agonist that has two centers of chirality and exists as four stereoisomers.	Fenoterol	11-14	adrenoceptor beta 2	Rattus norvegicus	21-31
19890360-0	2009	Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.	Fenoterol	0-9	CD14 molecule	Homo sapiens	79-83
20837485-6	2010	A similar partial beta(2)AR activation signal was revealed for the synthetic agonists fenoterol and terbutaline.	Fenoterol	86-95	adrenoceptor beta 2	Homo sapiens	18-27
20837485-8	2010	In contrast, fenoterol was quite efficient in triggering beta-arrestin2 recruitment to the cell surface and its interaction with beta(2)AR, as well as internalization of the receptors, whereas norepinephrine caused partial and slow changes in these assays.	Fenoterol	13-22	arrestin beta 2	Homo sapiens	57-71
20837485-8	2010	In contrast, fenoterol was quite efficient in triggering beta-arrestin2 recruitment to the cell surface and its interaction with beta(2)AR, as well as internalization of the receptors, whereas norepinephrine caused partial and slow changes in these assays.	Fenoterol	13-22	adrenoceptor beta 2	Homo sapiens	129-138
20144591-0	2010	The effect of stereochemistry on the thermodynamic characteristics of the binding of fenoterol stereoisomers to the beta(2)-adrenoceptor.	Fenoterol	85-94	adrenoceptor beta 2	Homo sapiens	116-136
20144591-1	2010	The binding thermodynamics of the stereoisomers of fenoterol, (R,R")-, (S,S")-, (R,S")-, and (S,R")-fenoterol, to the beta(2)-adrenergic receptor (beta(2)-AR) have been determined.	Fenoterol	51-60	adrenoceptor beta 2	Homo sapiens	118-145
20144591-1	2010	The binding thermodynamics of the stereoisomers of fenoterol, (R,R")-, (S,S")-, (R,S")-, and (S,R")-fenoterol, to the beta(2)-adrenergic receptor (beta(2)-AR) have been determined.	Fenoterol	51-60	adrenoceptor beta 2	Homo sapiens	147-157
19683054-8	2010	Compared to paired controls, fenoterol up-regulated the mRNAs of cytokines/proteins implicated in the recruitment of T and B cells or the activation and proliferation of bronchial epithelial cells (CCL20/MIP-3alpha, FOXA2, PPAR-gamma) in isolated bronchi and in cultured epithelial cells.	Fenoterol	29-38	C-C motif chemokine ligand 20	Homo sapiens	198-203
19683054-8	2010	Compared to paired controls, fenoterol up-regulated the mRNAs of cytokines/proteins implicated in the recruitment of T and B cells or the activation and proliferation of bronchial epithelial cells (CCL20/MIP-3alpha, FOXA2, PPAR-gamma) in isolated bronchi and in cultured epithelial cells.	Fenoterol	29-38	C-C motif chemokine ligand 20	Homo sapiens	204-214
19683054-8	2010	Compared to paired controls, fenoterol up-regulated the mRNAs of cytokines/proteins implicated in the recruitment of T and B cells or the activation and proliferation of bronchial epithelial cells (CCL20/MIP-3alpha, FOXA2, PPAR-gamma) in isolated bronchi and in cultured epithelial cells.	Fenoterol	29-38	forkhead box A2	Homo sapiens	216-221
19683054-8	2010	Compared to paired controls, fenoterol up-regulated the mRNAs of cytokines/proteins implicated in the recruitment of T and B cells or the activation and proliferation of bronchial epithelial cells (CCL20/MIP-3alpha, FOXA2, PPAR-gamma) in isolated bronchi and in cultured epithelial cells.	Fenoterol	29-38	peroxisome proliferator activated receptor gamma	Homo sapiens	223-233
19683054-9	2010	Fenoterol exposure significantly enhanced CD8(+)-T and differentiated CD138(+)-B-cells infiltration into the bronchi, especially the subepithelial area.	Fenoterol	0-9	CD8a molecule	Homo sapiens	42-45
19683054-9	2010	Fenoterol exposure significantly enhanced CD8(+)-T and differentiated CD138(+)-B-cells infiltration into the bronchi, especially the subepithelial area.	Fenoterol	0-9	syndecan 1	Homo sapiens	70-75
19683054-10	2010	Increase in CD8 or CD138 labeling-intensity strongly correlated with rise in maximal contraction to endothelin-1 induced by fenoterol exposure.	Fenoterol	124-133	CD8a molecule	Homo sapiens	12-15
19683054-10	2010	Increase in CD8 or CD138 labeling-intensity strongly correlated with rise in maximal contraction to endothelin-1 induced by fenoterol exposure.	Fenoterol	124-133	syndecan 1	Homo sapiens	19-24
19683054-10	2010	Increase in CD8 or CD138 labeling-intensity strongly correlated with rise in maximal contraction to endothelin-1 induced by fenoterol exposure.	Fenoterol	124-133	endothelin 1	Homo sapiens	100-112
20036561-0	2010	Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.	Fenoterol	40-49	adrenoceptor beta 2	Homo sapiens	113-140
19890360-0	2009	Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.	Fenoterol	0-9	arrestin beta 2	Homo sapiens	150-165
19890360-0	2009	Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.	Fenoterol	0-9	GLI family zinc finger 2	Homo sapiens	169-174
19890360-1	2009	AIM: To investigate the molecular mechanism and signaling pathway by which fenoterol, a beta(2)-adrenergic receptor (beta(2)-AR) agonist, produces anti-inflammatory effects.	Fenoterol	75-84	adrenoceptor beta 2	Homo sapiens	88-115
19890360-1	2009	AIM: To investigate the molecular mechanism and signaling pathway by which fenoterol, a beta(2)-adrenergic receptor (beta(2)-AR) agonist, produces anti-inflammatory effects.	Fenoterol	75-84	adrenoceptor beta 2	Homo sapiens	117-127
19890360-4	2009	RESULTS: LPS-induced membrane-bound CD14, TLR4/CD14 complex levels and elevation of inflammatory cytokines were all significantly reduced by pre-incubation of fenoterol (P<0.05).	Fenoterol	159-168	CD14 molecule	Homo sapiens	36-40
19890360-4	2009	RESULTS: LPS-induced membrane-bound CD14, TLR4/CD14 complex levels and elevation of inflammatory cytokines were all significantly reduced by pre-incubation of fenoterol (P<0.05).	Fenoterol	159-168	toll like receptor 4	Homo sapiens	42-46
19890360-4	2009	RESULTS: LPS-induced membrane-bound CD14, TLR4/CD14 complex levels and elevation of inflammatory cytokines were all significantly reduced by pre-incubation of fenoterol (P<0.05).	Fenoterol	159-168	CD14 molecule	Homo sapiens	47-51
19703961-6	2009	In contrast to zinterol, stimulation of I(Ca,L) by fenoterol (fen-beta(2)-AR), a beta(2)-AR agonist that acts exclusively via G(s) signalling, was smaller in +LMN than LMN myocytes.	Fenoterol	51-60	adrenoceptor beta 2	Homo sapiens	81-91
20144591-5	2010	All of the fenoterol stereoisomers are full agonists of the beta(2)-AR, and, therefore, the results of this study are inconsistent with the previously described "thermodynamic agonist-antagonist discrimination", in which the binding of an agonist to the beta-AR is entropy-driven and the binding of an antagonist is enthalpy-driven.	Fenoterol	11-20	adrenoceptor beta 2	Homo sapiens	60-70
19890360-0	2009	Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.	Fenoterol	0-9	toll like receptor 4	Homo sapiens	85-89
19890360-0	2009	Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.	Fenoterol	0-9	CD14 molecule	Homo sapiens	90-94
19788733-4	2009	METHODS: IL-8 release was assessed via ELISA under basal condition and after stimulation with bradykinin alone or in combination with fenoterol, the Epac activators 8-pCPT-2"-O-Me-cAMP and Sp-8-pCPT-2"-O-Me-cAMPS, the PKA activator 6-Bnz-cAMP and the cGMP analog 8-pCPT-2"-O-Me-cGMP.	Fenoterol	134-143	C-X-C motif chemokine ligand 8	Homo sapiens	9-13
19788733-11	2009	RESULTS: The beta2-agonist fenoterol augmented release of IL-8 by bradykinin.	Fenoterol	27-36	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	13-18
19788733-11	2009	RESULTS: The beta2-agonist fenoterol augmented release of IL-8 by bradykinin.	Fenoterol	27-36	C-X-C motif chemokine ligand 8	Homo sapiens	58-62
19788733-11	2009	RESULTS: The beta2-agonist fenoterol augmented release of IL-8 by bradykinin.	Fenoterol	27-36	kininogen 1	Homo sapiens	66-76
19259901-2	2009	The aim of this study was to analyse the relevance of long-term tocolysis with beta-2-mimetics (Fenoterol) at a single centre over a period of three years.	Fenoterol	96-105	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	79-85
19703961-6	2009	In contrast to zinterol, stimulation of I(Ca,L) by fenoterol (fen-beta(2)-AR), a beta(2)-AR agonist that acts exclusively via G(s) signalling, was smaller in +LMN than LMN myocytes.	Fenoterol	51-60	adrenoceptor beta 2	Homo sapiens	66-76
19429833-7	2009	Propranolol (1 microM) inhibited the rise in NO induced by isoproterenol or the beta(2)-adrenoceptor agonists salbutamol, terbutaline, or fenoterol.	Fenoterol	138-147	adrenoceptor beta 2	Rattus norvegicus	80-100
19334040-9	2009	Both alpha1-agonists and propranolol (beta-blocker) increased HOB replication but fenoterol, a beta2-agonist, inhibited it.	Fenoterol	82-91	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	95-100
19334040-10	2009	Fenoterol nearly doubled RANKL mRNA and this was inhibited by propranolol.	Fenoterol	0-9	TNF superfamily member 11	Homo sapiens	25-30
19462961-1	2009	Phenolic beta(2)-adrenoreceptor agonists salbutamol, fenoterol, and terbutaline relax smooth muscle cells that relieve acute airway bronchospasm associated with asthma.	Fenoterol	53-62	adrenoceptor beta 2	Homo sapiens	9-31
19535704-12	2009	Fenoterol-treated rats showed a significant decrease in IL-6 and TNF-alpha levels and in the wet/dry weight ratio of the lungs.	Fenoterol	0-9	interleukin 6	Rattus norvegicus	56-60
19535704-12	2009	Fenoterol-treated rats showed a significant decrease in IL-6 and TNF-alpha levels and in the wet/dry weight ratio of the lungs.	Fenoterol	0-9	tumor necrosis factor	Rattus norvegicus	65-74
19535704-15	2009	CONCLUSIONS: Fenoterol inhalation improved oxygenation after 270 and 360 min, attenuated the release of TNF-alpha and IL-6, and diminished the lung edema and infiltration of polymorphonuclear leukocytes.	Fenoterol	13-22	tumor necrosis factor	Rattus norvegicus	104-113
19535704-15	2009	CONCLUSIONS: Fenoterol inhalation improved oxygenation after 270 and 360 min, attenuated the release of TNF-alpha and IL-6, and diminished the lung edema and infiltration of polymorphonuclear leukocytes.	Fenoterol	13-22	interleukin 6	Rattus norvegicus	118-122
19462961-0	2009	Peroxidative metabolism of beta2-agonists salbutamol and fenoterol and their analogues.	Fenoterol	57-66	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	27-32
19001067-7	2009	(p. 158) show that stereoisomers of the beta(2)-adrenoceptor selective agonist fenoterol differentially activates G(s)- and G(i)-proteins in native rat cardiomyocytes.	Fenoterol	79-88	adrenoceptor beta 2	Rattus norvegicus	40-60
18775853-8	2008	Selective beta1-AR blockade did not affect the action of clenbuterol on sarcomere shortening but significantly reduced contractility in the presence of fenoterol and salbutamol (P < 0.05).	Fenoterol	152-161	adrenoceptor beta 1	Homo sapiens	10-18
18641310-8	2008	In human monocytes, epinephrine and the beta(2) adrenoreceptor agonist fenoterol potently inhibited LPS-induced TNF-alpha and IL-12, but stimulated IL-10 production.	Fenoterol	71-80	interleukin 10	Homo sapiens	148-153
18838481-2	2009	Our previous studies have demonstrated that although most beta(2)-adrenoceptor agonists activate both G(s) and G(i) proteins, fenoterol, a full agonist of beta(2)-adrenoceptor, selectively activates G(s) protein.	Fenoterol	126-135	adrenoceptor beta 2	Homo sapiens	155-175
18641310-8	2008	In human monocytes, epinephrine and the beta(2) adrenoreceptor agonist fenoterol potently inhibited LPS-induced TNF-alpha and IL-12, but stimulated IL-10 production.	Fenoterol	71-80	adrenoceptor beta 2	Homo sapiens	40-62
18641310-8	2008	In human monocytes, epinephrine and the beta(2) adrenoreceptor agonist fenoterol potently inhibited LPS-induced TNF-alpha and IL-12, but stimulated IL-10 production.	Fenoterol	71-80	tumor necrosis factor	Homo sapiens	112-121
16448568-8	2006	Our data support the existence of differences between these six genotypes both in the shape of the dose response relationship of the beta2-adrenoceptor agonist fenoterol as well as in the propensity to develop tolerance for these effects by pre-treatment with terbutaline.	Fenoterol	160-169	adrenoceptor beta 2	Homo sapiens	133-151
17890476-9	2007	The addition of the beta2-adrenergic fenoterol provided greater additional bronchodilatation than the short-acting anticholinergic ipratropium.	Fenoterol	37-46	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	20-25
17047523-4	2006	Administration of LPS (0.4, 1, and 1.5 mg/kg), under continuous infusion of vasopressin, dose-dependently amplified the chronotropic response to isoprenaline, prenalterol, and fenoterol (by 80%, 50%, and 100%, respectively) but not to CGP 12177.	Fenoterol	176-185	arginine vasopressin	Rattus norvegicus	76-87
18770048-1	2008	The aim of this study was to formulate extended release compression coated core tablets of fenoterol hydrobromide, a selective beta(2) adrenergic receptor agonist, in an attempt to prevent nocturnal asthma.	Fenoterol	91-113	beta-2 adrenergic receptor	Canis lupus familiaris	127-154
17848804-5	2008	We studied allergen-induced changes in sputum chemokines, migration of peripheral blood T cells and control of beta2-agonist fenoterol over T cell migration and alpha-CD3/alpha-CD28-induced cytokine production.	Fenoterol	125-134	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	111-116
17845020-0	2007	Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.	Fenoterol	70-79	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	19-24
17845020-1	2007	The structure of fenoterol, a beta2-adrenoceptor agonist used in therapy, has been joined with furoxan NO-donor moieties to give new NO-donor beta2-agonists.	Fenoterol	17-26	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	30-35
17845020-1	2007	The structure of fenoterol, a beta2-adrenoceptor agonist used in therapy, has been joined with furoxan NO-donor moieties to give new NO-donor beta2-agonists.	Fenoterol	17-26	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	142-147
17506540-0	2007	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.	Fenoterol	76-85	adrenoceptor beta 2	Homo sapiens	119-144
17506540-0	2007	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.	Fenoterol	90-99	adrenoceptor beta 2	Homo sapiens	119-144
17506540-1	2007	Stereoisomers of fenoterol and six fenoterol derivatives have been synthesized and their binding affinities for the beta2 adrenergic receptor (Kibeta2-AR), the subtype selectivity relative to the beta1-AR (Kibeta1-AR/Kibeta2-AR) and their functional activities were determined.	Fenoterol	17-26	adrenoceptor beta 2	Homo sapiens	116-141
16917835-1	2006	BACKGROUND: rac-Fenoterol is a beta2-adrenoceptor agonist (beta2-AR) used in the treatment of asthma.	Fenoterol	16-25	adrenoceptor beta 2	Homo sapiens	31-49
16917835-1	2006	BACKGROUND: rac-Fenoterol is a beta2-adrenoceptor agonist (beta2-AR) used in the treatment of asthma.	Fenoterol	16-25	adrenoceptor beta 2	Homo sapiens	59-67
16917835-12	2006	DISCUSSION: Previous studies have shown that rac-fenoterol acts as an apparent beta2-AR/G(s) selective agonist and fully restores diminished beta2-AR contractile response in cardiomyocytes from failing hearts of spontaneously hypertensive rats (SHR).	Fenoterol	49-58	adrenoceptor beta 2	Homo sapiens	79-87
16917835-12	2006	DISCUSSION: Previous studies have shown that rac-fenoterol acts as an apparent beta2-AR/G(s) selective agonist and fully restores diminished beta2-AR contractile response in cardiomyocytes from failing hearts of spontaneously hypertensive rats (SHR).	Fenoterol	49-58	adrenoceptor beta 2	Homo sapiens	141-149
16973691-1	2006	The beta(2)-adrenoceptor (beta(2)-AR) agonists clenbuterol and fenoterol have similar beneficial effects in animal models of heart failure.	Fenoterol	63-72	adrenoceptor beta 2	Rattus norvegicus	4-24
16973691-1	2006	The beta(2)-adrenoceptor (beta(2)-AR) agonists clenbuterol and fenoterol have similar beneficial effects in animal models of heart failure.	Fenoterol	63-72	adrenoceptor beta 2	Rattus norvegicus	26-36
16820175-1	2006	Chronic exposure of human isolated bronchi to beta2-adrenergic agonists, especially fenoterol, potentiates smooth muscle contraction in response to endothelin-1 (ET-1), a peptide implicated in chronic inflammatory airway diseases.	Fenoterol	84-93	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	46-51
16820175-1	2006	Chronic exposure of human isolated bronchi to beta2-adrenergic agonists, especially fenoterol, potentiates smooth muscle contraction in response to endothelin-1 (ET-1), a peptide implicated in chronic inflammatory airway diseases.	Fenoterol	84-93	endothelin 1	Homo sapiens	148-160
16820175-1	2006	Chronic exposure of human isolated bronchi to beta2-adrenergic agonists, especially fenoterol, potentiates smooth muscle contraction in response to endothelin-1 (ET-1), a peptide implicated in chronic inflammatory airway diseases.	Fenoterol	84-93	endothelin 1	Homo sapiens	162-166
16340002-1	2006	Chronic exposure of human isolated bronchi to beta(2)-adrenergic agonists, especially fenoterol, potentiates smooth muscle contraction in response to endothelin-1 (ET-1), a peptide implicated in chronic inflammatory airway diseases.	Fenoterol	86-95	endothelin 1	Homo sapiens	150-162
16340002-1	2006	Chronic exposure of human isolated bronchi to beta(2)-adrenergic agonists, especially fenoterol, potentiates smooth muscle contraction in response to endothelin-1 (ET-1), a peptide implicated in chronic inflammatory airway diseases.	Fenoterol	86-95	endothelin 1	Homo sapiens	164-168
16340002-2	2006	Our objective was to determine whether ET-1 receptors ETA and ETB are involved in fenoterol enhancement.	Fenoterol	82-91	endothelin 1	Homo sapiens	39-43
16340002-2	2006	Our objective was to determine whether ET-1 receptors ETA and ETB are involved in fenoterol enhancement.	Fenoterol	82-91	endothelin receptor type A	Homo sapiens	54-57
16340002-2	2006	Our objective was to determine whether ET-1 receptors ETA and ETB are involved in fenoterol enhancement.	Fenoterol	82-91	endothelin receptor type B	Homo sapiens	62-65
16340002-3	2006	Twenty-two human bronchi were sensitized to ET-1 by prolonged incubation with 0.1 microM fenoterol (15 h, 21 degrees C).	Fenoterol	89-98	endothelin 1	Homo sapiens	44-48
16340002-6	2006	ETA and ETB receptor mRNA expressions were 1.27- +/- 0.14-fold (not significant) and 2.24- +/- 0.28-fold (P<0.01) higher, respectively, in fenoterol-treated bronchi than in paired controls.	Fenoterol	142-151	endothelin receptor type A	Homo sapiens	0-3
16340002-6	2006	ETA and ETB receptor mRNA expressions were 1.27- +/- 0.14-fold (not significant) and 2.24- +/- 0.28-fold (P<0.01) higher, respectively, in fenoterol-treated bronchi than in paired controls.	Fenoterol	142-151	endothelin receptor type B	Homo sapiens	8-11
16340002-7	2006	Fenoterol incubation significantly increased epithelial ETA and ETB receptor labeling intensity scores (P=0.001 and P=0.002, respectively, versus controls), and enhanced the diffuse localization of ETA receptors on the epithelial cells (P=0.002 versus controls), but did not change the ETB-receptor immunolabeling intensity on airway smooth muscle.	Fenoterol	0-9	endothelin receptor type A	Homo sapiens	56-59
16340002-7	2006	Fenoterol incubation significantly increased epithelial ETA and ETB receptor labeling intensity scores (P=0.001 and P=0.002, respectively, versus controls), and enhanced the diffuse localization of ETA receptors on the epithelial cells (P=0.002 versus controls), but did not change the ETB-receptor immunolabeling intensity on airway smooth muscle.	Fenoterol	0-9	endothelin receptor type B	Homo sapiens	64-67
16340002-7	2006	Fenoterol incubation significantly increased epithelial ETA and ETB receptor labeling intensity scores (P=0.001 and P=0.002, respectively, versus controls), and enhanced the diffuse localization of ETA receptors on the epithelial cells (P=0.002 versus controls), but did not change the ETB-receptor immunolabeling intensity on airway smooth muscle.	Fenoterol	0-9	endothelin receptor type A	Homo sapiens	198-201
16340002-7	2006	Fenoterol incubation significantly increased epithelial ETA and ETB receptor labeling intensity scores (P=0.001 and P=0.002, respectively, versus controls), and enhanced the diffuse localization of ETA receptors on the epithelial cells (P=0.002 versus controls), but did not change the ETB-receptor immunolabeling intensity on airway smooth muscle.	Fenoterol	0-9	endothelin receptor type B	Homo sapiens	286-289
16340002-8	2006	We conclude that fenoterol-induced sensitization of human isolated bronchi involves epithelial ETA and ETB receptors, which suggests perturbation of the epithelial regulation of airway smooth muscle contraction in response to ET-1.	Fenoterol	17-26	endothelin receptor type A	Homo sapiens	95-98
16340002-8	2006	We conclude that fenoterol-induced sensitization of human isolated bronchi involves epithelial ETA and ETB receptors, which suggests perturbation of the epithelial regulation of airway smooth muscle contraction in response to ET-1.	Fenoterol	17-26	endothelin receptor type B	Homo sapiens	103-106
16340002-8	2006	We conclude that fenoterol-induced sensitization of human isolated bronchi involves epithelial ETA and ETB receptors, which suggests perturbation of the epithelial regulation of airway smooth muscle contraction in response to ET-1.	Fenoterol	17-26	endothelin 1	Homo sapiens	226-230
16324695-1	2006	Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the beta(2)-adrenoceptor.	Fenoterol	110-119	adrenoceptor beta 2	Bos taurus	291-311
15749741-6	2005	Finally, in contrast to CREB, phosphorylation of Src and extracellular signal-regulated kinase was enhanced by fenoterol upon TARC pretreatment.	Fenoterol	111-120	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	49-52
16129733-8	2005	Alprenolol inhibited fenoterol-induced beta3-adrenoceptor responses while acting as an agonist at higher concentrations.	Fenoterol	21-30	adrenoceptor beta 3	Homo sapiens	39-57
15749741-6	2005	Finally, in contrast to CREB, phosphorylation of Src and extracellular signal-regulated kinase was enhanced by fenoterol upon TARC pretreatment.	Fenoterol	111-120	C-C motif chemokine ligand 17	Homo sapiens	126-130
15965358-1	2005	We examined whether the beta2-adrenoceptor agonists fenoterol and salbutamol, the beta3-adrenoceptor agonists CL 316243 and ZD 2079, and the agonists of the low-affinity state of beta-adrenoceptors, cyanopindolol and CGP 12177 block alpha1-adrenoceptors in that concentration range in which they relax the human pulmonary and rat mesenteric arteries preconstricted with phenylephrine 10 microM and 1 microM, respectively.	Fenoterol	52-61	adrenoceptor beta 2	Homo sapiens	24-42
16147906-2	2005	We examined whether the beta2-adrenoceptor agonists, procaterol and fenoterol, induce human Per1 mRNA expression in human bronchial epithelium.	Fenoterol	68-77	adrenoceptor beta 2	Homo sapiens	24-42
15749741-3	2005	In the present study we demonstrate that the C-C chemokine thymus and activation-regulated chemokine (TARC) impairs the ability of beta(2)-agonist fenoterol to activate the cAMP downstream effector cAMP-responsive element binding protein (CREB) in freshly isolated human T cells.	Fenoterol	147-156	C-C motif chemokine ligand 17	Homo sapiens	102-106
15749741-3	2005	In the present study we demonstrate that the C-C chemokine thymus and activation-regulated chemokine (TARC) impairs the ability of beta(2)-agonist fenoterol to activate the cAMP downstream effector cAMP-responsive element binding protein (CREB) in freshly isolated human T cells.	Fenoterol	147-156	cAMP responsive element binding protein 1	Homo sapiens	198-237
15749741-3	2005	In the present study we demonstrate that the C-C chemokine thymus and activation-regulated chemokine (TARC) impairs the ability of beta(2)-agonist fenoterol to activate the cAMP downstream effector cAMP-responsive element binding protein (CREB) in freshly isolated human T cells.	Fenoterol	147-156	cAMP responsive element binding protein 1	Homo sapiens	239-243
15728216-13	2005	Intravenous tocolysis with the beta2-adrenergic receptor agonist fenoterol leads to complete desensitization of the beta-adrenergic receptor system.	Fenoterol	65-74	adrenoceptor beta 2	Homo sapiens	31-56
15479951-2	2005	In rats, the age-related decrease in the maximal rate of relaxation is reversed after 4-wk administration with the beta2-adrenoceptor agonist (beta2-agonist) fenoterol.	Fenoterol	158-167	adrenoceptor beta 2	Rattus norvegicus	115-133
15479951-6	2005	Fenoterol treatment increased the Vmax of SERCA and SERCA1 protein levels in RG and WG.	Fenoterol	0-9	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1	Rattus norvegicus	52-58
15715182-4	2005	Traditional beta2-adrenoceptor agonists (beta2-agonists), such as salbutamol, terbutaline and fenoterol, were characterised by a rapid onset but relatively short duration of action.	Fenoterol	94-103	adrenoceptor beta 2	Homo sapiens	12-30
15715182-4	2005	Traditional beta2-adrenoceptor agonists (beta2-agonists), such as salbutamol, terbutaline and fenoterol, were characterised by a rapid onset but relatively short duration of action.	Fenoterol	94-103	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-17
16147906-4	2005	Moreover, fenoterol or procaterol induced the phosphorylation of CREB in BEAS-2B cells as verified by immunoblot analysis.	Fenoterol	10-19	cAMP responsive element binding protein 1	Homo sapiens	65-69
14571280-2	2003	The fenoterol-induced beta2-adrenoceptor desensitization was not affected by pretreatment with either genistein, a broad-spectrum tyrosine kinase inhibitor, or PP2, a specific Src family tyrosine kinase inhibitor.	Fenoterol	4-13	beta-2 adrenergic receptor	Cavia porcellus	22-40
15351928-0	2004	Nociceptin inhibits vanilloid TRPV-1-mediated neurosensitization induced by fenoterol in human isolated bronchi.	Fenoterol	76-85	prepronociceptin	Homo sapiens	0-10
15351928-0	2004	Nociceptin inhibits vanilloid TRPV-1-mediated neurosensitization induced by fenoterol in human isolated bronchi.	Fenoterol	76-85	transient receptor potential cation channel subfamily V member 1	Homo sapiens	30-36
15351928-1	2004	Chronic exposure to beta(2)-adrenoceptor agonists, especially fenoterol, has been shown to increase smooth muscle contraction to endothelin-1 in human bronchi partly through tachykinin-mediated pathways.	Fenoterol	62-71	adrenoceptor beta 2	Homo sapiens	20-40
15351928-1	2004	Chronic exposure to beta(2)-adrenoceptor agonists, especially fenoterol, has been shown to increase smooth muscle contraction to endothelin-1 in human bronchi partly through tachykinin-mediated pathways.	Fenoterol	62-71	endothelin 1	Homo sapiens	129-141
15351928-2	2004	The purpose of this work was to further investigate the role of sensory nerves in fenoterol-induced sensitization of human airways and the effect of nociceptin, a nociceptin/orphanin FQ (NOP) receptor agonist, on the increase in contraction after fenoterol exposure.	Fenoterol	247-256	prepronociceptin	Homo sapiens	149-159
15351928-3	2004	Human bronchi from 62 patients were sensitized to endothelin-1 by prolonged incubation with fenoterol (0.1 microM, 15 h).	Fenoterol	92-101	endothelin 1	Homo sapiens	50-62
15351928-4	2004	The sensitizing effect of fenoterol was inhibited by high concentration of capsaicin (10 microM, 30 min before fenoterol sensitization), which induces depletion of mediators from sensory nerves, or co-incubation of fenoterol and capsazepine (1 microM), a vanilloid TRPV-1 receptor antagonist.	Fenoterol	26-35	transient receptor potential cation channel subfamily V member 1	Homo sapiens	265-271
15351928-5	2004	Moreover, short pretreatment of bronchi with capsaicin (10 microM) or capsazepine (1 microM) after sensitization by fenoterol decreased the rise in smooth muscle contraction to endothelin-1.	Fenoterol	116-125	endothelin 1	Homo sapiens	177-189
15351928-6	2004	Nociceptin (1 microM) also inhibited the increased contraction in fenoterol-sensitized bronchi.	Fenoterol	66-75	prepronociceptin	Homo sapiens	0-10
15351928-8	2004	In conclusion, fenoterol induces sensitization of human isolated bronchi to endothelin-1 in part through the stimulation of the vanilloid TRPV-1 receptor on tachykininergic sensory nerves.	Fenoterol	15-24	endothelin 1	Homo sapiens	76-88
15351928-8	2004	In conclusion, fenoterol induces sensitization of human isolated bronchi to endothelin-1 in part through the stimulation of the vanilloid TRPV-1 receptor on tachykininergic sensory nerves.	Fenoterol	15-24	transient receptor potential cation channel subfamily V member 1	Homo sapiens	138-144
14617677-1	2004	The beta2-adrenoceptor agonist (beta2-agonist) fenoterol has potent anabolic effects on rat skeletal muscle.	Fenoterol	47-56	adrenoceptor beta 2	Rattus norvegicus	4-22
15257628-2	2004	Berodual is a fixed combination of the anticholinergic agent ipratropium bromide (IB) and the beta2-adrenergic agonist fenoterol hydrobromide (FEN).	Fenoterol	119-141	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	94-99
15257628-2	2004	Berodual is a fixed combination of the anticholinergic agent ipratropium bromide (IB) and the beta2-adrenergic agonist fenoterol hydrobromide (FEN).	Fenoterol	143-146	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	94-99
15278905-2	2004	We investigated the level of uterine OTR mRNA expression after the administration of Beta(2)-AR agonists fenoterol and hexoprenaline to rats from day 18 to 22 of pregnancy, and also tested the effect of fenoterol on uterine explants.	Fenoterol	105-114	oxytocin receptor	Rattus norvegicus	37-40
15278905-4	2004	Fenoterol in vivo elicited a maximum 125% increase of OTR mRNA, in vitro produced a maximum fourfold increase in OTR mRNA.	Fenoterol	0-9	oxytocin receptor	Rattus norvegicus	54-57
15278905-4	2004	Fenoterol in vivo elicited a maximum 125% increase of OTR mRNA, in vitro produced a maximum fourfold increase in OTR mRNA.	Fenoterol	0-9	oxytocin receptor	Rattus norvegicus	113-116
14607853-0	2004	Beta2-adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury.	Fenoterol	27-36	adrenoceptor beta 2	Rattus norvegicus	0-18
14607853-1	2004	Beta(2)-adrenoceptor agonists such as fenoterol are anabolic in skeletal muscle, and because they promote hypertrophy and improve force-producing capacity, they have potential application for enhancing muscle repair after injury.	Fenoterol	38-47	adrenoceptor beta 2	Rattus norvegicus	0-20
12427489-7	2002	Compared to control tissues, NK(1)R and NK(2)R mRNA expression was increased by about 1.6-fold and 1.4-fold, respectively, in tissues treated with fenoterol.	Fenoterol	147-156	substance-P receptor	Cavia porcellus	29-35
14719995-5	2003	The Saskatchewan study not only found an increased risk of death among patients dispensed fenoterol, but also suggested this might be a class effect of beta(2)-agonists.	Fenoterol	90-99	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	152-158
12873495-1	2003	The (18)F-labeled beta2-adrenergic receptor ligand (R,R)(S,S) 5-(2-(2-[4-(2-[(18)F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol, a derivative of the original highly selective racemic fenoterol, was synthesized in an overall radiochemical yield of 20% after 65 min with a radiochemical purity higher than 98%.	Fenoterol	212-221	beta-2 adrenergic receptor	Cavia porcellus	18-43
12721099-10	2003	In both Th1 and Th2 cells, the induction of CREB phosphorylation by beta(2)-agonist fenoterol was impaired.	Fenoterol	84-93	negative elongation factor complex member C/D	Homo sapiens	8-11
12721099-10	2003	In both Th1 and Th2 cells, the induction of CREB phosphorylation by beta(2)-agonist fenoterol was impaired.	Fenoterol	84-93	cAMP responsive element binding protein 1	Homo sapiens	44-48
12661144-0	2003	Behaviour of beta 2-adrenoceptors on lymphocytes under continuous and pulsatile tocolysis with Fenoterol.	Fenoterol	95-104	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	13-19
12661144-6	2003	Our data demonstrate that continuous administration of the short-acting beta 2-agonist Fenoterol resulted in a substantial loss of beta 2-adrenoceptors on lymphocytes.	Fenoterol	87-96	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	72-78
12661144-6	2003	Our data demonstrate that continuous administration of the short-acting beta 2-agonist Fenoterol resulted in a substantial loss of beta 2-adrenoceptors on lymphocytes.	Fenoterol	87-96	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	131-137
12427489-7	2002	Compared to control tissues, NK(1)R and NK(2)R mRNA expression was increased by about 1.6-fold and 1.4-fold, respectively, in tissues treated with fenoterol.	Fenoterol	147-156	substance-K receptor	Cavia porcellus	40-46
12427489-9	2002	In conclusion, fenoterol induces tracheal hyperresponsiveness to NKA and an up-regulation of NK(1)R and NK(2)R gene expression.	Fenoterol	15-24	substance-P receptor	Cavia porcellus	93-99
12427489-9	2002	In conclusion, fenoterol induces tracheal hyperresponsiveness to NKA and an up-regulation of NK(1)R and NK(2)R gene expression.	Fenoterol	15-24	substance-K receptor	Cavia porcellus	104-110
12388476-2	2002	Although the beta(2)-adrenoceptor agonist clenbuterol has well-characterized effects on skeletal muscle, less is known about the therapeutic potential of the related beta(2)-adrenoceptor agonist fenoterol.	Fenoterol	195-204	adrenoceptor beta 2	Rattus norvegicus	166-186
12452831-0	2002	Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions.	Fenoterol	14-23	adrenoceptor beta 2	Homo sapiens	64-82
12452831-8	2002	Fenoterol inhibited platelet-activating factor (PAF)-induced O2- generation by eosinophils significantly more than salbutamol or procaterol.	Fenoterol	0-9	PCNA clamp associated factor	Homo sapiens	20-46
12452831-8	2002	Fenoterol inhibited platelet-activating factor (PAF)-induced O2- generation by eosinophils significantly more than salbutamol or procaterol.	Fenoterol	0-9	PCNA clamp associated factor	Homo sapiens	48-51
12452831-9	2002	Fenoterol partially inhibited PAF-induced degranulation by eosinophils similarly to salbutamol or procaterol.	Fenoterol	0-9	PCNA clamp associated factor	Homo sapiens	30-33
12452831-12	2002	Fenoterol, but not salbutamol or procaterol, significantly inhibited PAF-induced eosinophil adhesion.	Fenoterol	0-9	PCNA clamp associated factor	Homo sapiens	69-72
12596892-0	2002	The beta2- and beta3-adrenoceptor-mediated relaxation induced by fenoterol in guinea pig taenia caecum.	Fenoterol	65-74	beta-2 adrenergic receptor	Cavia porcellus	4-33
12376356-1	2002	Incubation of human distal bronchi from 48 patients for 15 h with 10(-7) M fenoterol induced sensitization characterized by an increase in maximal contraction to endothelin-1 (ET-1) and acetylcholine (ACh).	Fenoterol	75-84	endothelin 1	Homo sapiens	162-174
12376356-1	2002	Incubation of human distal bronchi from 48 patients for 15 h with 10(-7) M fenoterol induced sensitization characterized by an increase in maximal contraction to endothelin-1 (ET-1) and acetylcholine (ACh).	Fenoterol	75-84	endothelin 1	Homo sapiens	176-180
12376356-4	2002	Our results suggest that chronic exposure to fenoterol induces proinflammatory effects mediated by nuclear factor-kappaB and pathways involving leukotrienes, prostanoids, bradykinin, tachykinins, protein kinase C, and p38(MAPK), leading to the regulation of smooth muscle contraction to ET-1 and ACh.	Fenoterol	45-54	kininogen 1	Homo sapiens	171-181
12376356-4	2002	Our results suggest that chronic exposure to fenoterol induces proinflammatory effects mediated by nuclear factor-kappaB and pathways involving leukotrienes, prostanoids, bradykinin, tachykinins, protein kinase C, and p38(MAPK), leading to the regulation of smooth muscle contraction to ET-1 and ACh.	Fenoterol	45-54	mitogen-activated protein kinase 14	Homo sapiens	218-221
12376356-4	2002	Our results suggest that chronic exposure to fenoterol induces proinflammatory effects mediated by nuclear factor-kappaB and pathways involving leukotrienes, prostanoids, bradykinin, tachykinins, protein kinase C, and p38(MAPK), leading to the regulation of smooth muscle contraction to ET-1 and ACh.	Fenoterol	45-54	endothelin 1	Homo sapiens	287-291
11885748-4	2001	The combination of the selective beta1-adrenoceptor antagonist (+/-)-atenolol (100 microM), and the selective beta2-adrenoceptor antagonist (+/-)-butoxamine (100 microM), produced a 2 and 6 fold rightward shift of the concentration-response curves for (+/-)-terbutaline and (+/-)-fenoterol respectively, without depressing the maximal responses.	Fenoterol	274-289	beta-2 adrenergic receptor	Cavia porcellus	110-128
12596892-6	2002	However, in the presence of 3 x 10(-4) M atenolol, 10(-4) M butoxamine and 10(-6) M phentolamine to block the beta1-, beta2- and a-adrenoceptor effects, respectively, Schild regression analysis carried out for bupranolol against fenoterol gave pA2 values of 5.80.	Fenoterol	229-238	beta-2 adrenergic receptor	Cavia porcellus	110-143
11974946-2	2002	We measured the pulmonary function, static respiratory pressures, and ventilation during exercise, before and after inhalation of the beta 2-adrenergic drug, fenoterol bromide (FB) in 12 male COPD patients (mean age 82.1 +/- 0.6 years old), QOL was measured with a St George"s Respiratory Questionnaire (SGRQ) in the patients.	Fenoterol	177-179	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	134-140
11755157-2	2001	In this study, we have assessed the effects of prostaglandin E(2) and the beta(2)-adrenoceptor agonist, fenoterol on RANTES (regulated upon activation, normal T cell expressed and secreted) release by these cells.	Fenoterol	104-113	adrenoceptor beta 2	Homo sapiens	74-94
11755157-2	2001	In this study, we have assessed the effects of prostaglandin E(2) and the beta(2)-adrenoceptor agonist, fenoterol on RANTES (regulated upon activation, normal T cell expressed and secreted) release by these cells.	Fenoterol	104-113	C-C motif chemokine ligand 5	Homo sapiens	117-123
11755157-4	2001	Prostaglandin E(2) and fenoterol, only in presence of a cyclo-oxygenase inhibitor indomethacin (10(-6) M), provoked a concentration-dependent reduction in RANTES release.	Fenoterol	23-32	C-C motif chemokine ligand 5	Homo sapiens	155-161
12154173-2	2002	When isoproterenol (ISO; 0.1 microM) plus the beta(2)-AR antagonist ICI 118,551 (ISO-beta(1)-AR stimulation) or 0.1 microM fenoterol, a beta(2)-AR agonist (FEN-beta(2)-AR stimulation) increased I(Ca,L), ACh (1 microM) inhibited I(Ca,L) by -60 +/- 4 and -63 +/- 6 %, respectively.	Fenoterol	123-132	adrenoceptor beta 2	Homo sapiens	136-146
12154173-2	2002	When isoproterenol (ISO; 0.1 microM) plus the beta(2)-AR antagonist ICI 118,551 (ISO-beta(1)-AR stimulation) or 0.1 microM fenoterol, a beta(2)-AR agonist (FEN-beta(2)-AR stimulation) increased I(Ca,L), ACh (1 microM) inhibited I(Ca,L) by -60 +/- 4 and -63 +/- 6 %, respectively.	Fenoterol	123-132	adrenoceptor beta 2	Homo sapiens	136-146
11755157-0	2001	RANTES release by human airway smooth muscle: effects of prostaglandin E(2) and fenoterol.	Fenoterol	80-89	C-C motif chemokine ligand 5	Homo sapiens	0-6
11730729-0	2001	Effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on contractile receptor function in airway smooth muscle.	Fenoterol	10-19	adrenoceptor beta 2	Bos taurus	41-61
11730729-1	2001	In the present study, we investigated the effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions.	Fenoterol	52-61	adrenoceptor beta 2	Bos taurus	83-103
11730729-7	2001	In conclusion, fenoterol-induced constitutive beta(2)-adrenoceptor activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol.	Fenoterol	15-24	adrenoceptor beta 2	Bos taurus	46-66
11885748-6	2001	In the presence of (+/-)-atenolol and (+/-)-butoxamine, however, the non-selective beta1, beta2- and beta3-adrenoceptor antagonist (+/-)-bupranolol caused a concentration-dependent rightward shift of the concentration-response curves for (+/-)-terbutaline and (+/-)-fenoterol.	Fenoterol	260-275	beta-3 adrenergic receptor	Cavia porcellus	101-119
11426849-1	2001	Prolonged (18 h) incubation of isolated bovine tracheal smooth muscle with the beta2-adrenoceptor agonist fenoterol (10 microM) induced desensitization of isoprenaline-induced adenylyl cyclase activity in bovine tracheal smooth muscle membranes, characterized by a 25% decrease in maximal effect (Emax) (P < 0.05), while the sensitivity to the agonist (pEC50) was unchanged.	Fenoterol	106-115	adrenoceptor beta 2	Bos taurus	79-97
11426849-5	2001	These data indicate that 18-h fenoterol treatment of bovine tracheal smooth muscle induces beta2-adrenoceptor desensitization and reduced functional antagonism of methacholine-induced contraction by beta-adrenoceptor agonists, without a change of muscarinic M2 receptor function.	Fenoterol	30-39	adrenoceptor beta 2	Bos taurus	91-109
11193379-7	2000	A beta-adrenoceptor agonists (beta-agonist), procaterol, clenbuterol, fenoterol and terbutaline suppressed the production of TNF- and IL-1 beta.	Fenoterol	70-79	tumor necrosis factor	Homo sapiens	125-128
11152649-6	2001	Addition of exogenous PGE2 or the beta2-agonist fenoterol, which increase cAMP, to cytokine-treated HASM cells had no effect on GM-CSF release unless COX activity was first blocked with indomethacin.	Fenoterol	48-57	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	34-39
11406052-16	2001	The beta2-agonists used were: fenoterol and metaproterenol.	Fenoterol	30-39	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-9
11232847-0	2001	High-performance liquid chromatographic determination of the beta2-selective adrenergic agonist fenoterol in human plasma after fluorescence derivatization.	Fenoterol	96-105	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	61-66
11232847-1	2001	A sensitive high-performance liquid chromatographic method has been developed for the determination of the beta2-selective adrenergic agonist fenoterol in human plasma.	Fenoterol	142-151	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	107-112
11232861-2	2001	After hydrolysis of the conjugates with beta-glucuronidase/arylsulfatase a derivatisation step with formaldehyde converts fenoterol, orciprenaline, reproterol and terbutaline to one derivative, a tetrahydroisoquinoline, while the other beta-2 agonists remain unchanged.	Fenoterol	122-131	glucuronidase beta	Homo sapiens	40-58
11232861-2	2001	After hydrolysis of the conjugates with beta-glucuronidase/arylsulfatase a derivatisation step with formaldehyde converts fenoterol, orciprenaline, reproterol and terbutaline to one derivative, a tetrahydroisoquinoline, while the other beta-2 agonists remain unchanged.	Fenoterol	122-131	arylsulfatase A	Homo sapiens	59-74
11232861-2	2001	After hydrolysis of the conjugates with beta-glucuronidase/arylsulfatase a derivatisation step with formaldehyde converts fenoterol, orciprenaline, reproterol and terbutaline to one derivative, a tetrahydroisoquinoline, while the other beta-2 agonists remain unchanged.	Fenoterol	122-131	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	236-242
11193379-7	2000	A beta-adrenoceptor agonists (beta-agonist), procaterol, clenbuterol, fenoterol and terbutaline suppressed the production of TNF- and IL-1 beta.	Fenoterol	70-79	interleukin 1 beta	Homo sapiens	134-143
10460759-2	1999	Because beta(2)-adrenoceptor agonists are the most widely used bronchodilators in asthma, we investigated the effects of the beta(2)-adrenoceptor agonist fenoterol on NK(2) receptor messenger RNA (mRNA) and receptor density as well as the functional responses of bovine tracheal smooth muscle to the NK(2) receptor agonist [beta-Ala(8)]-NKA(4-10) in vitro, using Northern blot analysis, receptor binding, and organ bath studies.	Fenoterol	154-163	tachykinin receptor 2	Bos taurus	167-181
11053211-2	2000	In bovine tracheal smooth muscle (BTSM), we investigated the effect of short and long term beta(2)-AR activation by fenoterol on constitutive receptor activity.	Fenoterol	116-125	adrenoceptor beta 2	Bos taurus	91-101
11053211-10	2000	In conclusion, fenoterol treatment of BTSM causes a time- and concentration-dependent development of constitutive beta(2)-AR activity, which can be reversed by various inverse agonists.	Fenoterol	15-24	adrenoceptor beta 2	Bos taurus	114-124
11080712-5	2000	RESULTS: A23187-induced EPO release from guinea pig eosinophils was inhibited in a concentration-dependent manner by pretreatment for 5 minutes with fenoterol, clenbuterol, and salbutamol.	Fenoterol	149-158	eosinophil peroxidase	Cavia porcellus	24-27
11080712-8	2000	The inhibitory effects of fenoterol and clenbuterol on A23187-induced EPO release were correlated with increases in the intracellular cAMP levels evoked by either compound.	Fenoterol	26-35	eosinophil peroxidase	Cavia porcellus	70-73
11080712-9	2000	After incubation of eosinophils with 10(-6) mol/L fenoterol for 120 minutes to induce complete desensitization of beta(2)-adrenoceptors, the inhibitory effects of theophylline and rolipram were increased by about 100-fold in the desensitized cells, although the effects of forskolin and dibutyryl cAMP were not affected by beta(2)-adrenoceptor desensitization.	Fenoterol	50-59	beta-2 adrenergic receptor	Cavia porcellus	114-134
11001174-2	2000	Beta-agonists, such as isoproterenol, salbutamol and fenoterol, effectively inhibited A23187-induced EPO release from guinea pig eosinophils.	Fenoterol	53-62	eosinophil peroxidase	Cavia porcellus	101-104
10779367-2	2000	In this study, we examined the effects of the beta(2)-adrenoceptor agonist, fenoterol, on the expression of H(1) receptors at the mRNA and protein levels, and functional responses.	Fenoterol	76-85	adrenoceptor beta 2	Bos taurus	46-66
10583037-6	1999	CONCLUSIONS: Stimulation of EPO production during fenoterol infusion appears to be angiotensin II-mediated.	Fenoterol	50-59	angiotensinogen	Homo sapiens	83-97
10460759-7	1999	Dexamethasone completely prevented the fenoterol-induced increase in NK(2) receptor mRNA and in the contractile response.	Fenoterol	39-48	tachykinin receptor 2	Homo sapiens	69-83
9517594-3	1998	This hypothesis derives from the ability of albuterol and fenoterol to inhibit the interaction of the glucocorticosteroid receptor (GR) with proinflammatory transcriptional activators acting on the promoter region of certain target genes that encode cytokines such as tumor necrosis factor-alpha (TNF alpha) and granulocyte/macrophage colony-stimulating factor (GM-CSF).	Fenoterol	58-67	tumor necrosis factor	Homo sapiens	268-295
10464825-3	1999	The present study was designed to test in vitro whether fenoterol, a short-acting beta 2-adrenoceptor agonist, could modify human blood neutrophil recruitment and antimicrobial activity.	Fenoterol	56-65	adrenoceptor beta 2	Homo sapiens	82-101
10464825-4	1999	Pre-exposure to fenoterol significantly reduced neutrophil migration towards the complement component C5a, at concentrations ranging from 10(-7) M to 10(-5) M, or towards lipopolysaccharide, at a concentration of 10(-5) M (P < 0.05, each comparison).	Fenoterol	16-25	complement C5a receptor 1	Homo sapiens	102-105
10464825-7	1999	These results suggest that short-acting beta 2-adrenoceptor agonists, such as fenoterol, are able partially to reduce neutrophil recruitment in the airways without interfering with the processes involved in phagocytic activity against bacteria.	Fenoterol	78-87	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	40-46
10070105-4	1999	Preincubation for 15 min with the selective beta2-adrenoceptor agonist fenoterol (1 microM) increased both ACh and NE overflow to 178 +/- 28 (P < 0.01) and 165 +/- 12% (P < 0.01), respectively, of control values, increases that were abolished completely by the selective beta2-adrenoceptor antagonist ICI-118551 (1 microM).	Fenoterol	71-80	beta-2 adrenergic receptor	Cavia porcellus	44-62
10070105-4	1999	Preincubation for 15 min with the selective beta2-adrenoceptor agonist fenoterol (1 microM) increased both ACh and NE overflow to 178 +/- 28 (P < 0.01) and 165 +/- 12% (P < 0.01), respectively, of control values, increases that were abolished completely by the selective beta2-adrenoceptor antagonist ICI-118551 (1 microM).	Fenoterol	71-80	beta-2 adrenergic receptor	Cavia porcellus	277-295
9730867-4	1998	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol.	Fenoterol	182-191	interferon gamma	Homo sapiens	31-40
9730867-4	1998	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol.	Fenoterol	182-191	interleukin 3	Homo sapiens	54-58
9730867-4	1998	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol.	Fenoterol	182-191	adrenoceptor beta 2	Homo sapiens	166-173
10583037-0	1999	Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system.	Fenoterol	0-9	erythropoietin	Homo sapiens	27-41
10583037-0	1999	Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system.	Fenoterol	0-9	renin	Homo sapiens	75-80
10583037-1	1999	AIMS: The present study assessed the hypothesis that the beta2 sympathomimetic fenoterol influences the production of erythropoietin (EPO) by activation of the renin angiotensin system (RAS), i.e. angiotensin II.	Fenoterol	79-88	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	57-62
10583037-1	1999	AIMS: The present study assessed the hypothesis that the beta2 sympathomimetic fenoterol influences the production of erythropoietin (EPO) by activation of the renin angiotensin system (RAS), i.e. angiotensin II.	Fenoterol	79-88	erythropoietin	Homo sapiens	118-132
10583037-1	1999	AIMS: The present study assessed the hypothesis that the beta2 sympathomimetic fenoterol influences the production of erythropoietin (EPO) by activation of the renin angiotensin system (RAS), i.e. angiotensin II.	Fenoterol	79-88	erythropoietin	Homo sapiens	134-137
10583037-1	1999	AIMS: The present study assessed the hypothesis that the beta2 sympathomimetic fenoterol influences the production of erythropoietin (EPO) by activation of the renin angiotensin system (RAS), i.e. angiotensin II.	Fenoterol	79-88	renin	Homo sapiens	160-165
10583037-1	1999	AIMS: The present study assessed the hypothesis that the beta2 sympathomimetic fenoterol influences the production of erythropoietin (EPO) by activation of the renin angiotensin system (RAS), i.e. angiotensin II.	Fenoterol	79-88	angiotensinogen	Homo sapiens	197-211
10583037-6	1999	CONCLUSIONS: Stimulation of EPO production during fenoterol infusion appears to be angiotensin II-mediated.	Fenoterol	50-59	erythropoietin	Homo sapiens	28-31
9517594-3	1998	This hypothesis derives from the ability of albuterol and fenoterol to inhibit the interaction of the glucocorticosteroid receptor (GR) with proinflammatory transcriptional activators acting on the promoter region of certain target genes that encode cytokines such as tumor necrosis factor-alpha (TNF alpha) and granulocyte/macrophage colony-stimulating factor (GM-CSF).	Fenoterol	58-67	tumor necrosis factor	Homo sapiens	297-306
9517594-3	1998	This hypothesis derives from the ability of albuterol and fenoterol to inhibit the interaction of the glucocorticosteroid receptor (GR) with proinflammatory transcriptional activators acting on the promoter region of certain target genes that encode cytokines such as tumor necrosis factor-alpha (TNF alpha) and granulocyte/macrophage colony-stimulating factor (GM-CSF).	Fenoterol	58-67	colony stimulating factor 2	Homo sapiens	312-360
9517594-3	1998	This hypothesis derives from the ability of albuterol and fenoterol to inhibit the interaction of the glucocorticosteroid receptor (GR) with proinflammatory transcriptional activators acting on the promoter region of certain target genes that encode cytokines such as tumor necrosis factor-alpha (TNF alpha) and granulocyte/macrophage colony-stimulating factor (GM-CSF).	Fenoterol	58-67	colony stimulating factor 2	Homo sapiens	362-368
9596107-3	1998	In a previous study of 64 asthmatics, most experienced a deterioration in asthma control during regular inhaled beta2-agonist (fenoterol) treatment, while a minority improved.	Fenoterol	127-136	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	112-117
9491829-0	1998	Fenoterol increases erythropoietin concentrations during tocolysis.	Fenoterol	0-9	erythropoietin	Homo sapiens	20-34
9491829-6	1998	CONCLUSIONS: The data confirm our earlier results that fenoterol increases EPO concentrations following haemorrhage.	Fenoterol	55-64	erythropoietin	Homo sapiens	75-78
9734347-0	1998	Downregulation of the expression of intercellular adhesion molecule (ICAM)-1 on bronchial epithelial cells by fenoterol, a beta2-adrenoceptor agonist.	Fenoterol	110-119	intercellular adhesion molecule 1	Homo sapiens	36-76
9734347-0	1998	Downregulation of the expression of intercellular adhesion molecule (ICAM)-1 on bronchial epithelial cells by fenoterol, a beta2-adrenoceptor agonist.	Fenoterol	110-119	adrenoceptor beta 2	Homo sapiens	123-141
9734347-8	1998	The significant increase in ICAM-1 expression on HBECs induced by rh IFN-gamma was inhibited, in a dose-dependent manner, by the two drugs, but fenoterol was more efficient than dexamethasone at all of the concentrations tested (p < 0.05, all comparisons).	Fenoterol	144-153	intercellular adhesion molecule 1	Homo sapiens	28-34
9734347-8	1998	The significant increase in ICAM-1 expression on HBECs induced by rh IFN-gamma was inhibited, in a dose-dependent manner, by the two drugs, but fenoterol was more efficient than dexamethasone at all of the concentrations tested (p < 0.05, all comparisons).	Fenoterol	144-153	interferon gamma	Homo sapiens	69-78
9608824-0	1998	Pharmacokinetics of beta2-sympathomimetics at the example of fenoterol and conclusion for the administration.	Fenoterol	61-70	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	20-25
9056046-10	1997	beta 2-AR partial agonist activity may also be expressed as antagonism in the presence of an exogenous full agonist, as for example attenuation of fenoterol induced responses by salmeterol.	Fenoterol	147-156	adrenoceptor beta 2	Homo sapiens	0-9
9127437-2	1997	The beta-agonists, procaterol, clenbuterol, fenoterol and terbutaline, inhibited TNF-alpha and IL-1 beta production in a concentration-dependent manner, whereas they had no effect on IL-8 production.	Fenoterol	44-53	tumor necrosis factor	Homo sapiens	81-90
9127437-2	1997	The beta-agonists, procaterol, clenbuterol, fenoterol and terbutaline, inhibited TNF-alpha and IL-1 beta production in a concentration-dependent manner, whereas they had no effect on IL-8 production.	Fenoterol	44-53	interleukin 1 beta	Homo sapiens	95-104
9295336-5	1997	The coupling efficiencies for betaAR agonist activation of adenylyl cyclase relative to epinephrine (100%) were 42% for fenoterol, 4.9% for albuterol, 2.5% for dobutamine, and 1.1% for ephedrine.	Fenoterol	120-129	adrenoceptor beta 2	Homo sapiens	30-36
9295336-6	1997	At concentrations of these agonists yielding >90% receptor occupancy, the rate and extent (0-30 min) of agonist-induced desensitization of betaAR activation of adenylyl cyclase followed the same order as coupling efficiency, i.e. epinephrine >/= fenoterol > albuterol > dobutamine > ephedrine.	Fenoterol	252-261	adrenoceptor beta 2	Homo sapiens	142-148
9295336-9	1997	The two strongest agonists, epinephrine and fenoterol, provoked 11-13-fold increases in the level of betaAR phosphorylation after just 1 min, whereas the weak agonists dobutamine and ephedrine caused only 3-4-fold increases, similar to levels induced by cAMP-dependent protein kinase activation with forskolin.	Fenoterol	44-53	adrenoceptor beta 2	Homo sapiens	101-107
9209250-0	1997	Fenoterol but not dobutamine increases erythropoietin production in humans.	Fenoterol	0-9	erythropoietin	Homo sapiens	39-53
9209250-7	1997	Plasma renin activity was significantly increased during dobutamine and fenoterol infusion.	Fenoterol	72-81	renin	Homo sapiens	7-12
9209250-8	1997	CONCLUSIONS: This study shows in a model of controlled, physiologic stimulation of renal erythropoietin production that the beta 2-adrenergic receptor agonist fenoterol but not the beta 1-adrenergic receptor agonist dobutamine is able to increase erythropoietin levels in humans.	Fenoterol	159-168	erythropoietin	Homo sapiens	89-103
9209250-8	1997	CONCLUSIONS: This study shows in a model of controlled, physiologic stimulation of renal erythropoietin production that the beta 2-adrenergic receptor agonist fenoterol but not the beta 1-adrenergic receptor agonist dobutamine is able to increase erythropoietin levels in humans.	Fenoterol	159-168	adrenoceptor beta 2	Homo sapiens	124-150
9209250-8	1997	CONCLUSIONS: This study shows in a model of controlled, physiologic stimulation of renal erythropoietin production that the beta 2-adrenergic receptor agonist fenoterol but not the beta 1-adrenergic receptor agonist dobutamine is able to increase erythropoietin levels in humans.	Fenoterol	159-168	erythropoietin	Homo sapiens	247-261
9059471-1	1997	BACKGROUND: It has previously been shown that fenoterol, a beta 2 adrenergic agonist, increases the ventilatory response to hypoxia (HVR) and hypercapnia (HCVR) in normal subjects.	Fenoterol	46-55	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	59-65
9012556-6	1997	Fenoterol is a beta 2-agonists with higher intrinsic activity than salbutamol and produces greater systemic effects at higher than conventional doses on a microgram equivalent basis, although even at 4000 micrograms such differences are unlikely to be clinically relevant.	Fenoterol	0-9	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	15-21
9012556-8	1997	The long-acting beta 2-agonist salmeterol, as a partial agonist, has the potential to attenuate the acute bronchodilator response to a higher activity beta 2-agonist such as salbutamol or fenoterol, although there is no evidence to date on whether this is relevant in the setting of acute asthma.	Fenoterol	188-197	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	16-22
8956629-1	1996	A previously published nested case-control study, the Saskatchewan Asthma Epidemiologic Project (SAEP) spanning 1980-1987, investigated the risk of fatal or near fatal asthma and found different risks for two inhaled beta 2-agonists, fenoterol and salbutamol.	Fenoterol	234-243	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	217-223
8777955-0	1996	Role of cyclic AMP in the modulation of IgE production by the beta 2-adrenoceptor agonist, fenoterol.	Fenoterol	91-100	adrenoceptor beta 2	Homo sapiens	62-81
8988485-9	1996	Fenoterol (1-1000 nM), a beta 2-adrenoceptor agonist, and angiotensin II (1-1000 nM) significantly increased noradrenaline release in a concentration-dependent manner.	Fenoterol	0-9	angiotensinogen	Homo sapiens	25-72
8797398-10	1996	Both beta 2-agonists caused a decrease in serum potassium level that was significantly greater in the fenoterol (0.23 +/- 0.04 mmol/L) than in the salbutamol (0.06 +/- 0.03 mmol/L) group (p = 0.0002).	Fenoterol	102-111	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	5-11
8730730-13	1996	Of the other commonly used beta 2-adrenoceptor agonists, fenoterol, and formoterol, but not salbutamol, caused moderate inhibition of neutrophil oxidant generation by a superoxide-scavenging mechanism.	Fenoterol	57-66	adrenoceptor beta 2	Homo sapiens	27-46
8851515-4	1996	The beta 1-adrenoceptor agonist, prenalterol, increased heart rate and the beta 2-adrenoceptor agonist, fenoterol, caused a fall in blood pressure.	Fenoterol	104-113	adrenoceptor beta 2	Rattus norvegicus	75-94
8851515-5	1996	The effect of prenalterol was antagonized by the beta 1-adrenoceptor antagonist, CGP 20712 0.1 mumol kg-1 and the action of fenoterol was attenuated by the beta 2-adrenoceptor antagonist, ICI 118551 0.1 mumol kg-1.	Fenoterol	124-133	adrenoceptor beta 2	Rattus norvegicus	156-175
9044471-7	1997	Using a concentration of 10(-4) M, reduction of cytotoxicity was quite different among beta(2)-agonists: fenoterol (97.8%) > isoproterenol (67.6% > salbutamol (41.8%) > terbutaline (30.5%) > ipratropium bromide (18.1%).	Fenoterol	105-114	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	87-93
9044471-9	1997	The cellular O2- production of freshly isolated PMN was significantly (p < 0.05, comparisons 0 vs. > or = 10(-7) M) reduced with fenoterol and isoproterenol at concentrations > or = 10(-7) M. Propranolol had no inhibitory effect on antioxidant properties of beta(2)-agonists.	Fenoterol	135-144	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	267-273
8694299-1	1996	This double-blind study investigates whether isoflurane/N2O anesthesia adds to the bronchodilating effect of the beta 2-adrenergic agonist, fenoterol, after an endotracheal tube (ETT)-induced increase in airway resistance.	Fenoterol	140-149	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	113-119
8777955-3	1996	Our results indicate that fenoterol (1 microM) potentiated IL-4-induced IgE production and IgE messenger ribonucleic acid (mRNA) expression.	Fenoterol	26-35	interleukin 4	Homo sapiens	59-63
8777955-8	1996	Fenoterol potentiated IL-4-induced IgE production from purified B-cells activated through their CD40 antigen.	Fenoterol	0-9	interleukin 4	Homo sapiens	22-26
8777955-8	1996	Fenoterol potentiated IL-4-induced IgE production from purified B-cells activated through their CD40 antigen.	Fenoterol	0-9	CD40 molecule	Homo sapiens	96-100
8777955-11	1996	Taken together, these results show that fenoterol potentiates the IL-4-induced IgE production via the cAMP pathway, but that this enhancement could not be explained by a direct effect on B-lymphocytes.	Fenoterol	40-49	interleukin 4	Homo sapiens	66-70
8658370-2	1996	The aim of the present study was to evaluate in vivo the beta 2 agonist/antagonist activity of salmeterol and formoterol at rest with low endogenous adrenergic tone, on exercise with raised endogenous adrenergic tone, and in the presence of fenoterol, an exogenous full beta 2 receptor agonist.	Fenoterol	241-250	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	57-63
8911881-1	1996	OBJECTIVE: To analyse fenoterol-induced tachycardia and hypokalaemia, the most important and most frequent adverse effects of tocolytic therapy with beta 2-adrenoceptor agonists in females of childbearing age.	Fenoterol	22-31	adrenoceptor beta 2	Homo sapiens	149-168
7576689-5	1995	The inhibitory activity of the beta 2 agonist fenoterol was attenuated after a prolonged (14-h) pretreatment step with isoprenaline (10(-5)M), whereas the inhibitory properties of other adenylate cyclase activators, prostaglandin E2 and forskolin, were not affected appreciably.	Fenoterol	46-55	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	31-37
8588826-2	1995	We observed that salbutamol and fenoterol potentiate the IL-4-induced IgE production from peripheral blood mononuclear cells.	Fenoterol	32-41	interleukin 4	Mus musculus	57-61
8588826-4	1995	Fenoterol also potentiated, but in a lesser extent, the IgE production from purified B lymphocytes stimulated by both IL-4 and CD40, suggesting that the activity of beta 2-adrenoceptor agonist is mediated through T lymphocyte or monocyte modulation.	Fenoterol	0-9	interleukin 4	Mus musculus	118-122
8588826-4	1995	Fenoterol also potentiated, but in a lesser extent, the IgE production from purified B lymphocytes stimulated by both IL-4 and CD40, suggesting that the activity of beta 2-adrenoceptor agonist is mediated through T lymphocyte or monocyte modulation.	Fenoterol	0-9	adrenergic receptor, beta 2	Mus musculus	165-184
7621901-3	1995	We report that in rat lung, the beta 2-adrenoceptor agonists, salbutamol and fenoterol, decrease the binding of glucocorticoid receptors to GRE, by 46 +/- 4% although it has no effect on the affinity or number of glucocorticoid receptors.	Fenoterol	77-86	adrenoceptor beta 2	Rattus norvegicus	32-51
7670735-10	1995	Bisindolylmaleimide (1 microM), a protein kinase C inhibitor, significantly reduced the facilitatory effect of BK (10 nM), angiotensin II (0.3 microM) and phorbol dibutyrate (0.1 and 1 microM) but not of fenoterol (1 microM).	Fenoterol	204-213	angiotensinogen	Rattus norvegicus	123-137
8646005-0	1995	-Glucose, insulin and C-peptide kinetics during tocolysis with oral fenoterol-.	Fenoterol	68-77	insulin	Homo sapiens	22-31
7600375-2	1995	We present evidence that salbutamol and fenoterol potentiated the IL-4-induced IgE production by human peripheral blood mononuclear cells (PBMC).	Fenoterol	40-49	interleukin 4	Homo sapiens	66-70
7600375-4	1995	Salbutamol and fenoterol inhibited interferon-(IFN)-gamma production by PHA-activated human PBMC suggesting that the blockade of the production of this cytokine could possibly explain the enhancement of IgE production.	Fenoterol	15-24	interferon gamma	Homo sapiens	35-57
7600375-5	1995	Salbutamol and fenoterol potentiated the IL-4-induced production of sCD23 whereas no effect on CD23 expression was observed.	Fenoterol	15-24	interleukin 4	Homo sapiens	41-45
7600375-5	1995	Salbutamol and fenoterol potentiated the IL-4-induced production of sCD23 whereas no effect on CD23 expression was observed.	Fenoterol	15-24	Fc epsilon receptor II	Homo sapiens	69-73
7796855-3	1995	Fenoterol- and BRL 37344-induced inhibition of the excitatory NANC response was blocked with high potency (pKB 8.77 and 9.07, respectively) by the selective beta 2-adrenoceptor antagonist, ICI 118,511 (erythro-1-(7-methylindan-4-yloxy)-3-(isopropylamino)-but an-2-ol).	Fenoterol	0-9	beta-2 adrenergic receptor	Cavia porcellus	157-176
7710446-1	1995	The beta 2-sympathomimetic drug fenoterol (fenoterol hydrobromide, CAS 1944-12-3, Partusisten) is routinely used to inhibit uterine contractions (tocolysis).	Fenoterol	32-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-10
7710446-1	1995	The beta 2-sympathomimetic drug fenoterol (fenoterol hydrobromide, CAS 1944-12-3, Partusisten) is routinely used to inhibit uterine contractions (tocolysis).	Fenoterol	43-65	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-10
8646005-1	1995	OBJECTIVE: The effect of oral fenoterol therapy (40 mg/day) on the kinetics of glucose, insulin and C-peptide during an oral glucose tolerance test (oGTT; 100 g glucose) was investigated in the third trimester.	Fenoterol	30-39	insulin	Homo sapiens	88-95
8646005-1	1995	OBJECTIVE: The effect of oral fenoterol therapy (40 mg/day) on the kinetics of glucose, insulin and C-peptide during an oral glucose tolerance test (oGTT; 100 g glucose) was investigated in the third trimester.	Fenoterol	30-39	insulin	Homo sapiens	100-109
8578014-0	1995	Pharmacokinetics and pharmacodynamics of beta 2-agonists (in the light of fenoterol).	Fenoterol	74-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	41-47
8578014-1	1995	As an example of beta 2-agonists fenoterol was used in this study on 27 patients with chronic obstructive airways diseases (COAD).	Fenoterol	33-42	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	17-23
8405009-9	1993	Both IL-1 and TNF production were significantly lower in patients receiving fenoterol plus flunisolide than in patients on fenoterol alone.	Fenoterol	76-85	interleukin 1 alpha	Homo sapiens	5-9
8103795-5	1993	The beta 2 adrenoceptor agonist, fenoterol, produced a dose-dependent increase in operant behavior but colonic temperature fell and thermal balance reflected the characteristic effects of a thermolytic agent.	Fenoterol	33-42	adrenoceptor beta 2	Homo sapiens	4-23
7686438-2	1993	As assessed by flow cytometry, incubation of U 937 cells in the presence of salbutamol, fenoterol or IL-4 induced a concentration- and time-dependent increase in CD23 expression, that was maximal after 48 hr and followed by a decrease thereafter.	Fenoterol	88-97	Fc epsilon receptor II	Homo sapiens	162-166
7686438-5	1993	The effect on CD23 expression of salbutamol and fenoterol, but not of IL-4, was blocked in the presence of D,L-propranolol (1 microM) or butoxamine (1 microM).	Fenoterol	48-57	Fc epsilon receptor II	Homo sapiens	14-18
8094228-2	1993	In the present report it was shown that beta 2-adrenoceptor agonists, salbutamol and fenoterol, potentiated the IL-4-induced IgE production without significantly affecting the expression of the low affinity receptor for IgE at the cell surface of monocytes and B lymphocytes.	Fenoterol	85-94	adrenoceptor beta 2	Homo sapiens	40-59
8094228-2	1993	In the present report it was shown that beta 2-adrenoceptor agonists, salbutamol and fenoterol, potentiated the IL-4-induced IgE production without significantly affecting the expression of the low affinity receptor for IgE at the cell surface of monocytes and B lymphocytes.	Fenoterol	85-94	interleukin 4	Homo sapiens	112-116
7921529-1	1994	We investigated whether the beta 2-agonists fenoterol and salbutamol decreased plasma selenium and glutathione peroxidase activity in patients with asthma as this may partially explain the findings of reduced selenium status in asthmatic patients.	Fenoterol	44-53	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-34
7509842-3	1994	Salbutamol and fenoterol alone elicited expression of the monomorphic beta 2-chain (CD18) of the leukocyte functional antigen (LFA1) family.	Fenoterol	15-24	integrin subunit beta 2	Homo sapiens	84-88
7509842-3	1994	Salbutamol and fenoterol alone elicited expression of the monomorphic beta 2-chain (CD18) of the leukocyte functional antigen (LFA1) family.	Fenoterol	15-24	integrin subunit alpha L	Homo sapiens	127-131
8103795-6	1993	The beta 1 agonist, prenalterol, had no apparent effect on thermoregulatory behavior, colonic temperature or thermal balance but it blocked the thermolytic effects of fenoterol when both agonists were coadministered.	Fenoterol	167-176	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	4-10
8102213-1	1993	BACKGROUND: The aim of the present study was to compare the dose related effects of fenoterol and salbutamol on cardiac beta 1 and beta 2 receptors using the beta 1 selective antagonist atenolol, in order to dissect out relative beta 1/beta 2 mediated responses.	Fenoterol	84-93	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	120-126
8102213-1	1993	BACKGROUND: The aim of the present study was to compare the dose related effects of fenoterol and salbutamol on cardiac beta 1 and beta 2 receptors using the beta 1 selective antagonist atenolol, in order to dissect out relative beta 1/beta 2 mediated responses.	Fenoterol	84-93	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	131-137
7683196-10	1993	The beta 2-agonists salbutamol and fenoterol strongly inhibited heparin release from mast cells.	Fenoterol	35-44	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-10
8405009-9	1993	Both IL-1 and TNF production were significantly lower in patients receiving fenoterol plus flunisolide than in patients on fenoterol alone.	Fenoterol	76-85	tumor necrosis factor	Homo sapiens	14-17
8405009-9	1993	Both IL-1 and TNF production were significantly lower in patients receiving fenoterol plus flunisolide than in patients on fenoterol alone.	Fenoterol	123-132	tumor necrosis factor	Homo sapiens	14-17
1348869-1	1992	Short acting beta 2-agonists, such as salbutamol, fenoterol and terbutaline, are the most potent bronchodilating agents in the treatment of acute asthmatic attacks.	Fenoterol	50-59	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	13-19
1395751-6	1992	We conclude that fenoterol inhaled at a dosage used in clinical practice significantly reduces Kpl but not Mgpl nor MgIE levels in healthy subjects, indicating a lower sensitivity of Mg++ ions to beta 2-adrenergic stimulation than K+ ions.	Fenoterol	17-26	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	196-202
1395751-7	1992	Beta 2-adrenergic-induced insulin secretion probably contributes to the hypokalemic effect of inhaled fenoterol.	Fenoterol	102-111	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-6
1358833-0	1992	Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol.	Fenoterol	99-108	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	55-61
1350995-1	1992	The potencies of the beta 1-adrenoceptor agonist, noradrenaline, and the beta 2-adrenoceptor agonist, fenoterol, at beta-adrenoceptors in portal vein were examined using preparations isolated from control, methimazole-treated or l-thyroxine-treated rats.	Fenoterol	102-111	adrenoceptor beta 2	Rattus norvegicus	73-92
1350995-4	1992	The beta 2-adrenoceptor antagonist, ICI 118,551, was approximately 3000 fold more potent than the beta 1-adrenoceptor antagonist, atenolol, in blocking the effects of fenoterol (pA2 9.32 and 5.88 respectively) and 400 times more potent in antagonising noradrenaline (pA2 8.96 vs. 6.23).	Fenoterol	167-176	adrenoceptor beta 2	Rattus norvegicus	4-23
1350995-4	1992	The beta 2-adrenoceptor antagonist, ICI 118,551, was approximately 3000 fold more potent than the beta 1-adrenoceptor antagonist, atenolol, in blocking the effects of fenoterol (pA2 9.32 and 5.88 respectively) and 400 times more potent in antagonising noradrenaline (pA2 8.96 vs. 6.23).	Fenoterol	167-176	adrenoceptor beta 1	Rattus norvegicus	98-117
1346340-8	1992	CONCLUSIONS: An increased risk of death or near death from asthma was associated with the regular use of inhaled beta 2-agonist bronchodilators, especially fenoterol.	Fenoterol	156-165	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	113-119
1347999-3	1992	At higher than recommended doses, in asthmatic patients, fenoterol appears to cause greater dose-related systemic beta 2-responses compared with salbutamol or terbutaline, although there is no evidence to suggest that fenoterol is any less beta 2-selective in vivo.	Fenoterol	57-66	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	114-120
1319343-3	1992	The results show that the presynaptic beta 2-adrenoceptor population in SHR responds to significantly lower dosages of fenoterol than that in WR.	Fenoterol	119-128	adrenoceptor beta 2	Rattus norvegicus	38-57
1348446-1	1992	1. alpha 1-Adrenoceptor (phenylephrine in the presence of propranolol) and beta 2-adrenoceptor (fenoterol)-mediated positive inotropic effects were investigated in human ventricular preparations isolated from five non-failing (prospective organ donors) and from eight explanted failing hearts with end-stage idiopathic dilative cardiomyopathy (NYHA IV).	Fenoterol	96-105	adrenoceptor beta 2	Homo sapiens	75-94
34902340-0	2022	Molecular basis for stereoselective transport of fenoterol by the organic cation transporters 1 and 2.	Fenoterol	49-58	solute carrier family 22 member 1	Homo sapiens	66-101
1346963-4	1992	In this respect, although fenoterol appears to cause greater extrapulmonary beta 2-mediated adverse effects at higher doses, there is no evidence to suggest that it is any less beta 2-selective.	Fenoterol	26-35	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	76-82
1671326-6	1991	The concept of increasing beta-2 selectivity for metaproterenol and fenoterol compared with isoproterenol are not supported in the clinical setting.	Fenoterol	68-77	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	26-32
1682274-3	1991	When a beta 2-adrenoceptor agonist, either salbutamol or fenoterol, was added to U937 cells or monocytes both the IL-4-induced CD23 expression and release were markedly up-regulated.	Fenoterol	57-66	adrenoceptor beta 2	Homo sapiens	7-26
1682274-3	1991	When a beta 2-adrenoceptor agonist, either salbutamol or fenoterol, was added to U937 cells or monocytes both the IL-4-induced CD23 expression and release were markedly up-regulated.	Fenoterol	57-66	interleukin 4	Homo sapiens	114-118
1682274-3	1991	When a beta 2-adrenoceptor agonist, either salbutamol or fenoterol, was added to U937 cells or monocytes both the IL-4-induced CD23 expression and release were markedly up-regulated.	Fenoterol	57-66	Fc epsilon receptor II	Homo sapiens	127-131
1682274-5	1991	The potentiating effect of salbutamol and fenoterol on CD23 expression and release was not observed when a beta-adrenoceptor antagonist, either D,L-propranolol (1 microM) or butoxamine (1 microM), was added to the incubation medium.	Fenoterol	42-51	Fc epsilon receptor II	Homo sapiens	55-59
1982263-1	1990	In rat vas deferens, the beta-adrenoceptor agonists, isoprenaline, salbutamol, terbutaline and fenoterol, inhibited the contractions elicited by transmural electrical stimuli to an extent which depended on voltage magnitude.	Fenoterol	95-104	arginine vasopressin	Rattus norvegicus	7-10
34781292-0	2022	Validation of Fenoterol to Study beta2-Adrenoceptor Function in the Rat Urinary Bladder.	Fenoterol	14-23	adrenoceptor beta 2	Rattus norvegicus	33-51
34781292-1	2022	Fenoterol is a beta2-adrenoceptor (AR)-selective agonist that is commonly used to investigate relaxation responses mediated by beta2-AR in smooth muscle preparations.	Fenoterol	0-9	adrenoceptor beta 2	Rattus norvegicus	15-33
34781292-1	2022	Fenoterol is a beta2-adrenoceptor (AR)-selective agonist that is commonly used to investigate relaxation responses mediated by beta2-AR in smooth muscle preparations.	Fenoterol	0-9	ferredoxin reductase	Rattus norvegicus	35-37
34781292-1	2022	Fenoterol is a beta2-adrenoceptor (AR)-selective agonist that is commonly used to investigate relaxation responses mediated by beta2-AR in smooth muscle preparations.	Fenoterol	0-9	adenosine A2a receptor	Rattus norvegicus	127-135
34781292-3	2022	We designed the present study to investigate whether fenoterol is a proper pharmacological tool to study beta2-AR-mediated relaxation responses in the rat urinary bladder.	Fenoterol	53-62	adenosine A2a receptor	Rattus norvegicus	105-113
1493852-0	1992	The pharmacokinetics of the beta 2-adrenoceptor agonist fenoterol in healthy women.	Fenoterol	56-65	adrenoceptor beta 2	Homo sapiens	28-47
1493852-4	1992	The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).	Fenoterol	23-32	CD59 molecule (CD59 blood group)	Homo sapiens	62-67
1493852-4	1992	The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).	Fenoterol	23-32	CD59 molecule (CD59 blood group)	Homo sapiens	85-90
1493852-4	1992	The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).	Fenoterol	23-32	CD59 molecule (CD59 blood group)	Homo sapiens	85-90
1493852-4	1992	The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).	Fenoterol	23-32	CD59 molecule (CD59 blood group)	Homo sapiens	85-90
1493852-4	1992	The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).	Fenoterol	23-32	CD59 molecule (CD59 blood group)	Homo sapiens	85-90
1493852-4	1992	The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).	Fenoterol	23-32	CD59 molecule (CD59 blood group)	Homo sapiens	85-90
1685947-13	1991	The beta 2-adrenoreceptor agonist Fenoterol was infused intravenously during clearance of an injected lipid emulsion.	Fenoterol	34-43	adrenoceptor beta 2	Rattus norvegicus	4-25
1978808-10	1990	Other beta-sympathomimetic agents such as dopamine, dobutamine, fenoterol, salbutamol, and terbutaline also stimulated myocardial G-6-PDH activity in a time- and dose-related manner.	Fenoterol	64-73	glucose-6-phosphate dehydrogenase	Rattus norvegicus	130-137
2158831-6	1990	The beta 1-adrenoceptor-selective agonist, RO363 was ten times more potent than the beta 2-adrenoceptor-selective agonist, fenoterol.	Fenoterol	123-132	adrenergic receptor, beta 2	Mus musculus	84-103
2178961-7	1990	Fenoterol, but not placebo, caused a significant increase in forced expiratory volume in one second (FEV1) (+34%, on average), associated with a significant decrease in PEEPi (-63%, on average) and a significant improvement in Pdi,max (+19%, on average).	Fenoterol	0-9	peptidyl arginine deiminase 1	Homo sapiens	227-230
2178961-8	1990	We conclude that: 1) intrinsic PEEP can be present in stable COPD patients due to increased airflow resistance; 2) fenoterol improved diaphragmatic strength (Pdi,max) in our COPD patients, possibly due to a decrease in lung volume.	Fenoterol	115-124	peptidyl arginine deiminase 1	Homo sapiens	158-161
2135210-1	1990	The aim of this study was to compare the bronchodilator response of patients with either stable asthma or stable chronic bronchitis to the acute administration of oxitropium bromide and a beta agonist (fenoterol) when given both separately and together in order to determine the responses of these two groups of patients and the optimal doses of these agents when given in combination.	Fenoterol	202-211	amyloid beta precursor protein	Homo sapiens	186-192
34902340-2	2022	Recent studies showed strong stereoselective effects in the cellular uptake of fenoterol by the organic cation transporters OCT1 and OCT2.	Fenoterol	79-88	solute carrier family 22 member 1	Homo sapiens	124-128
34902340-2	2022	Recent studies showed strong stereoselective effects in the cellular uptake of fenoterol by the organic cation transporters OCT1 and OCT2.	Fenoterol	79-88	solute carrier family 22 member 2	Homo sapiens	133-137
34902340-4	2022	Our results suggest that the observed 1.9-fold higher maximum transport velocity (vmax) for (R,R)- over (S,S)-fenoterol in OCT1 is because the enantiomers bind to two distinct binding sites.	Fenoterol	104-119	solute carrier family 22 member 1	Homo sapiens	123-127
34902340-8	2022	Unlike for OCT1, both fenoterol enantiomers bind in the same region in OCT2 but in different conformations.	Fenoterol	22-31	solute carrier family 22 member 2	Homo sapiens	71-75
34902340-9	2022	Mutating THR246, predicted to interact with (S,S)-fenoterol in OCT2, led to an 11-fold decreased vmax.	Fenoterol	44-59	solute carrier family 22 member 2	Homo sapiens	63-67
34902340-10	2022	Altogether, our mutagenesis results correlate relatively well with our computational predictions and thereby provide an experimentally-corroborated hypothesis for the strong and contrasting enantiopreference in fenoterol uptake by OCT1 and OCT2.	Fenoterol	211-220	solute carrier family 22 member 1	Homo sapiens	231-235
34902340-10	2022	Altogether, our mutagenesis results correlate relatively well with our computational predictions and thereby provide an experimentally-corroborated hypothesis for the strong and contrasting enantiopreference in fenoterol uptake by OCT1 and OCT2.	Fenoterol	211-220	solute carrier family 22 member 2	Homo sapiens	240-244
35454354-0	2022	Hemi-Babim and Fenoterol as Potential Inhibitors of MPro and Papain-like Protease against SARS-CoV-2: An In-Silico Study.	Fenoterol	15-24	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	52-56
34274846-9	2021	The beta2-adrenoreceptor agonist, fenoterol, caused significantly more sIgA secretion than the control, and more sIgA secretion than the beta1-adrenoreceptor agonist, xamoterol.	Fenoterol	34-43	adrenoceptor beta 2	Rattus norvegicus	4-24
34472448-1	2021	Heart rate variability (HRV) and cardiorespiratory phase synchronization (CRPS) were employed to study the cardio- and respiratory interactions in patients with asthma receiving inhalation of beta2-agonist (Berotec 200 mcg) for routine bronchodilator test.	Fenoterol	207-214	ATPase H+ transporting V0 subunit a2	Homo sapiens	192-197
35563491-8	2022	Dog OCT1 transported fenoterol with 12.9-fold higher capacity but 14.3-fold lower affinity (higher KM) than human OCT1.	Fenoterol	21-30	solute carrier family 22 member 1	Homo sapiens	4-8
35563491-8	2022	Dog OCT1 transported fenoterol with 12.9-fold higher capacity but 14.3-fold lower affinity (higher KM) than human OCT1.	Fenoterol	21-30	solute carrier family 22 member 1	Homo sapiens	114-118
35563491-10	2022	Compared to human OCT2, dog OCT2 showed 10-fold lower transport of fenoterol and butylscopolamine.	Fenoterol	67-76	POU class 2 homeobox 2	Homo sapiens	18-22
35563491-10	2022	Compared to human OCT2, dog OCT2 showed 10-fold lower transport of fenoterol and butylscopolamine.	Fenoterol	67-76	solute carrier family 22 member 2	Canis lupus familiaris	28-32
35469921-5	2022	We found the beta2-adrenergic drug fenoterol was transported with 8-fold higher affinity by human OCT1, but at 9-fold lower capacity.	Fenoterol	35-44	ATPase H+ transporting V0 subunit a2	Homo sapiens	13-18
35469921-5	2022	We found the beta2-adrenergic drug fenoterol was transported with 8-fold higher affinity by human OCT1, but at 9-fold lower capacity.	Fenoterol	35-44	solute carrier family 22 member 1	Homo sapiens	98-102
35469921-10	2022	Comparison of the uptake of structurally similar beta2-adrenergics and molecular docking analyses indicated the second phenol ring, 3.3-4.8 A from the protonated amino group, as essential for the affinity for fenoterol conferred by Cys36.	Fenoterol	209-218	G protein-coupled receptor 162	Mus musculus	49-54
35216120-7	2022	Interestingly, OCT1 substrates exhibiting stronger OCT1 inhibition were mainly biaromatic beta-agonistic drugs, such as dobutamine, fenoterol, ractopamine and ritodrine.	Fenoterol	132-141	solute carrier family 22 member 1	Homo sapiens	15-19
35216120-7	2022	Interestingly, OCT1 substrates exhibiting stronger OCT1 inhibition were mainly biaromatic beta-agonistic drugs, such as dobutamine, fenoterol, ractopamine and ritodrine.	Fenoterol	132-141	solute carrier family 22 member 1	Homo sapiens	51-55
35454354-7	2022	Fenoterol is a beta-2 adrenergic agonist used for the symptomatic treatment of asthma as a bronchodilator and tocolytic.	Fenoterol	0-9	ATPase H+ transporting V0 subunit a2	Homo sapiens	15-21
2573312-1	1989	Administration of the beta 2 adrenergic agonists fenoterol, salbutamol and terbutaline to volunteers significantly reduced plasma potassium concentration in a double-blind crossover study.	Fenoterol	49-58	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-28
2532922-9	1989	Fenoterol also caused a mean increase of 8.7 beats min-1 in heart rate, 5 min after inhalation.	Fenoterol	0-9	CD59 molecule (CD59 blood group)	Homo sapiens	51-56
3290078-3	1988	beta 2-stimulation with fenoterol for 25 minutes caused glucose intolerance and insulin resistance for 4 hours.	Fenoterol	24-33	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-6
2904778-0	1988	Attenuation of bronchofiberscopy-induced cough by an inhaled beta 2-adrenergic agonist, fenoterol.	Fenoterol	88-97	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	61-67
2446520-0	1987	Fenoterol, a selective beta 2-adrenergic agonist, and inhibition of IgE-mediated basophil histamine release.	Fenoterol	0-9	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	23-29
3208783-1	1988	We investigated the effect of Fenoterol, a selective beta 2 adrenoceptor stimulant, on mucociliary clearance in 12 patients with chronic bronchitis.	Fenoterol	30-39	adrenoceptor beta 2	Homo sapiens	53-72
3170057-2	1988	Following our recent investigations into the influence of some drugs (cromolyn, ketotifen, theophylline) on the immune response, in this study we analyzed the in vitro effects of fenoterol (beta-2-adrenergic agonist) on the immune response.	Fenoterol	179-188	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	190-196
2446520-1	1987	The present study was undertaken to evaluate the effect of fenoterol, a selective beta 2-adrenergic agonist, on basophil histamine release.	Fenoterol	59-68	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	82-88
2889607-1	1987	Using a model of passive anaphylactic bronchoconstriction in the rat, the combined inhibitory effects of sodium cromoglycate and the beta 2-adrenoceptor agonists fenoterol and salbutamol were shown to be synergistic.	Fenoterol	162-171	adrenoceptor beta 2	Rattus norvegicus	133-152
3035960-1	1987	The aim of the study was to investigate whether topical application of a beta-2-adrenostimulant (fenoterol) on the mucous membrane has a clinically significant anti-allergic effect.	Fenoterol	97-106	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
2882568-2	1986	The studies suggest that the use of a combination of anticholinergic and beta 2-adrenergic drugs is justified, because the dominant mechanism in bronchospasm is the effect of acetylcholine on muscarinic receptors and because ipratropium bromide increases the action of fenoterol, so as to obtain prolonged bronchospasmolytic and antibronchoconstrictive effects with halved doses of beta 2-agonist.	Fenoterol	269-278	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
2870555-10	1986	Anomalies may exist in the banning of 2 beta 2-adrenoceptor agonists, fenoterol and orciprenaline (metaproterenol).	Fenoterol	70-79	adrenoceptor beta 2	Homo sapiens	40-59
3809697-4	1986	The reversibility of airflow obstruction by beta-2-sympathomimetics (Fenoterol) was the same with or without changes in the sinuses.	Fenoterol	69-78	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	44-50
4014869-10	1985	Pretreatment with 600 micrograms of aerosolized fenoterol significantly improved the PD20FEV1 values in 11 subjects with COPD (1.26 to 6.16 mumol; p less than 0.001).	Fenoterol	48-57	COPD	Homo sapiens	121-125
2864159-2	1985	The fenoterol aerosol contains a more potent beta 2-adrenergic agonist dose per puff than the other aerosols but, when given in equipotent doses, offers no advantage over available agents.	Fenoterol	4-13	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	45-51
2884705-3	1987	Tulobuterol and fenoterol improved mC of the total, central and peripheral bronchial tree significantly in comparison to the pretreatment values (p less than 0.001) reaching, after beta 2-agonist therapy, values observed in normal subjects.	Fenoterol	16-25	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	181-187
3096339-6	1986	UDPGT activity towards fenoterol is restricted to the liver and intestine and is not induced by PB, 3MC or A1254.	Fenoterol	23-32	UDP glucuronosyltransferase family 2 member B15	Rattus norvegicus	0-5
3085356-2	1986	A broncho-selective beta 2-adrenoceptor agonist fenoterol was able to prevent the antigen-induced leukotriene release completely, whereas the Ca++-ionophore induced leukotriene release was only moderately inhibited.	Fenoterol	48-57	adrenoceptor beta 2	Homo sapiens	20-39
2951804-0	1986	Prevention of fog-induced bronchospasm by Duovent and its components (fenoterol, ipratropium bromide) in asthmatics.	Fenoterol	70-79	zinc finger protein, FOG family member 1	Homo sapiens	14-17
2951806-0	1986	Histamine-induced bronchial response after administration of placebo, salbutamol and a combination of a beta-2-adrenergic drug (fenoterol) with an anticholinergic agent (ipratropium bromide) in asymptomatic asthma patients.	Fenoterol	128-137	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	104-110
4052734-4	1985	5 The high ratio (about 180) of the ECm for noradrenaline (beta-adrenoceptor agonist) to that for fenoterol (beta 2-adrenoceptor agonist), and the lack of effect of prenalterol (beta 1-adrenoceptor agonist) suggested that beta 2-adrenoceptors are preferentially involved in the relaxant activity of beta-adrenoceptor stimulants in this preparation.	Fenoterol	98-107	beta-2 adrenergic receptor	Cavia porcellus	109-128
2860336-1	1985	The effect of inhalation of fenoterol, a beta 2-agonist, on plasma potassium was studied in four groups of four healthy young subjects.	Fenoterol	28-37	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	41-47
2991865-4	1985	The beta 2 selectivity of fenoterol at normal oral and inhaled doses is the same as for albuterol and terbutaline.	Fenoterol	26-35	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-10
4013446-0	1985	[Changes in erythrocyte P50 and its effect on O2 transport in intravenous tocolysis with fenoterol (Partusisten)].	Fenoterol	89-98	nuclear factor kappa B subunit 1	Homo sapiens	24-27
3974172-5	1985	The beta 1-selective antagonist atenolol (2 mumol l-1) and the beta 2-selective antagonist ICI 118551 (1 mumol l-1) shifted the concentration-response curve of fenoterol to the right, indicating that beta 1- and beta 2-adrenoceptors may contribute to the positive inotropic effect of fenoterol.	Fenoterol	160-169	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	4-10
3974172-5	1985	The beta 1-selective antagonist atenolol (2 mumol l-1) and the beta 2-selective antagonist ICI 118551 (1 mumol l-1) shifted the concentration-response curve of fenoterol to the right, indicating that beta 1- and beta 2-adrenoceptors may contribute to the positive inotropic effect of fenoterol.	Fenoterol	160-169	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	63-69
3974172-5	1985	The beta 1-selective antagonist atenolol (2 mumol l-1) and the beta 2-selective antagonist ICI 118551 (1 mumol l-1) shifted the concentration-response curve of fenoterol to the right, indicating that beta 1- and beta 2-adrenoceptors may contribute to the positive inotropic effect of fenoterol.	Fenoterol	160-169	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	200-218
3974172-5	1985	The beta 1-selective antagonist atenolol (2 mumol l-1) and the beta 2-selective antagonist ICI 118551 (1 mumol l-1) shifted the concentration-response curve of fenoterol to the right, indicating that beta 1- and beta 2-adrenoceptors may contribute to the positive inotropic effect of fenoterol.	Fenoterol	284-293	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	200-218
3974172-7	1985	The results indicate that: (1) fenoterol exerts a direct positive inotropic effect in the human heart which may support the beneficial effects of the reduction of systemic vascular resistance in patients with congestive heart failure; (2) this positive inotropic effect of fenoterol is mediated by beta 1- and beta 2-adrenoceptors; (3) the clinically observed improvement of cardiac performance in the case of salbutamol is presumably not due to any direct positive inotropic effect.	Fenoterol	31-40	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	298-304
3974172-7	1985	The results indicate that: (1) fenoterol exerts a direct positive inotropic effect in the human heart which may support the beneficial effects of the reduction of systemic vascular resistance in patients with congestive heart failure; (2) this positive inotropic effect of fenoterol is mediated by beta 1- and beta 2-adrenoceptors; (3) the clinically observed improvement of cardiac performance in the case of salbutamol is presumably not due to any direct positive inotropic effect.	Fenoterol	31-40	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	310-316
6084778-4	1984	The beta 1-agonist dobutamine and the beta 2-agonists fenoterol and procaterol activated adenylate cyclase with an intrinsic activity of 0.5-0.7 (isoprenaline = 1.0).	Fenoterol	54-63	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-44
2418475-0	1985	[Cardiac tolerance of a beta-2-sympathomimetic spray: fenoterol.	Fenoterol	54-63	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	24-30
6084782-3	1984	In human right atrium, however, the beta 2-selective agonists fenoterol and salbutamol were relatively much more active.	Fenoterol	62-71	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	36-42
6732039-1	1984	Fenoterol ( Berotec ; Th 1165a , Boehringer- Ingelheim , Spa., Firenze , Italy) is an effective, widely used bronchodilator.	Fenoterol	0-9	surfactant protein A2	Homo sapiens	57-60
6386936-1	1984	In a double-blind crossover trial the beta 2-agonist fenoterol was administered by the nose and by mouth in 10 patients with stable asthma.	Fenoterol	53-62	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-44
6559719-0	1984	[Influence of fenoterol, ritodrine and clenbuterol on maternal oxytocin and PGFM levels].	Fenoterol	14-23	oxytocin/neurophysin I prepropeptide	Homo sapiens	63-71
6734028-3	1984	Heart rate (HR) and systolic (SBP) and diastolic (DBP) blood pressure responses to fenoterol were small (means +/- SE; HR: +4 +/- 1.3 bpm; SBP: +6 +/- 1.3 mm Hg; DBP: -3 +/- 1.4 mm Hg).	Fenoterol	83-92	selenium binding protein 1	Homo sapiens	30-33
6734028-3	1984	Heart rate (HR) and systolic (SBP) and diastolic (DBP) blood pressure responses to fenoterol were small (means +/- SE; HR: +4 +/- 1.3 bpm; SBP: +6 +/- 1.3 mm Hg; DBP: -3 +/- 1.4 mm Hg).	Fenoterol	83-92	D-box binding PAR bZIP transcription factor	Homo sapiens	50-53
6734028-3	1984	Heart rate (HR) and systolic (SBP) and diastolic (DBP) blood pressure responses to fenoterol were small (means +/- SE; HR: +4 +/- 1.3 bpm; SBP: +6 +/- 1.3 mm Hg; DBP: -3 +/- 1.4 mm Hg).	Fenoterol	83-92	selenium binding protein 1	Homo sapiens	139-142
6734028-3	1984	Heart rate (HR) and systolic (SBP) and diastolic (DBP) blood pressure responses to fenoterol were small (means +/- SE; HR: +4 +/- 1.3 bpm; SBP: +6 +/- 1.3 mm Hg; DBP: -3 +/- 1.4 mm Hg).	Fenoterol	83-92	D-box binding PAR bZIP transcription factor	Homo sapiens	162-165
6699315-1	1984	We have studied the effect of fenoterol, a selective beta-2 adrenergic agent, on airway obstruction in children with asthma.	Fenoterol	30-39	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	53-59
6559719-7	1984	Oral administration of Fenoterol inhibited the PG induced rise of the Oxytocin level and kept the Oxytocin level in the same range as following the administration of a Placebo.	Fenoterol	23-32	oxytocin/neurophysin I prepropeptide	Homo sapiens	70-78
6559719-7	1984	Oral administration of Fenoterol inhibited the PG induced rise of the Oxytocin level and kept the Oxytocin level in the same range as following the administration of a Placebo.	Fenoterol	23-32	oxytocin/neurophysin I prepropeptide	Homo sapiens	98-106
6135325-2	1983	Activity of microsomal phospholipase A2 in rat lung can be inhibited by in vivo application of the beta-adrenergic drug fenoterol both in control and diseased animals.	Fenoterol	120-129	phospholipase A2 group IB	Rattus norvegicus	23-39
6203844-0	1984	Inhibition of IgE-mediated histamine release from human basophils and mast cells by fenoterol.	Fenoterol	84-93	immunoglobulin heavy constant epsilon	Homo sapiens	14-17
6203844-1	1984	Fenoterol, a beta 2-adrenergic agonist recently introduced to treat asthmatic disorders, inhibits antigen-induced histamine release from human basophil leukocytes and lung mast cells in a dose-dependent fashion.	Fenoterol	0-9	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	13-19
6203844-3	1984	The relationship between the effect of fenoterol and cAMP level is supported by the finding that the beta 2-adrenergic agonist only inhibits the first stage of antigen-induced histamine release and not the release caused by the Ca2+ ionophore, A23187.	Fenoterol	39-48	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	101-107
6203844-4	1984	Propranolol, a competitive antagonist of beta 2-adrenergic receptor, blocks the inhibition of release and the cAMP accumulation caused by fenoterol.	Fenoterol	138-147	adrenoceptor beta 2	Homo sapiens	41-67
6203844-6	1984	These data suggest that fenoterol may modulate the in vivo release of the mediators of immediate hypersensitivity reactions via the activation of beta 2-adrenergic receptor linked to adenylate cyclase on human basophils and mast cells.	Fenoterol	24-33	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	146-152
6197312-1	1983	The inhibitory effects of fenoterol, a beta 2-adrenoceptor agonist, on the release of SRS-A leukotrienes and histamine from chopped human lung tissue were measured and selective beta-adrenoceptor antagonists used to investigate the nature of the receptors involved.	Fenoterol	26-35	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	39-45
6197312-3	1983	Propranolol 0.1 and 1.0 microM and butoxamine 10 and 100 microM significantly antagonized the effects of fenoterol 0.1 microM on SRS-A and histamine at concentrations which affect (beta 2-adrenoceptors, while atenolol 0.1 to 10 microM showed no antagonism at concentrations which affect beta 1-adrenoceptors.	Fenoterol	105-114	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	181-187
6123517-0	1982	A time-saving method for the determination of the beta 2 sympathomimetics terbutaline, salbutamol and fenoterol.	Fenoterol	102-111	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	50-56
6218610-7	1982	It is concluded that the beta 1-antagonist celiprolol does not induce relevant airway obstruction in patients with bronchial asthma, and that an additional infusion of aminophylline enhances the bronchodilatory effect of the beta 2-agonist fenoterol (p less than 0.05).	Fenoterol	240-249	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	225-231
6352305-0	1983	The anti-allergic effect of the beta 2-adrenergic agent fenoterol in the nose.	Fenoterol	56-65	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	32-38
336305-7	1977	The therapeutic efficacy of fenoterol was sustained throughout this three-month study, and suggests that this relatively selective beta2 adrenergic drug will provide a well tolerated, alternative aerosol for chronic use in asthma.	Fenoterol	28-37	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	131-136
6114186-1	1981	The acute hemodynamic effects of the semiselective beta 2-stimulating compound Fenoterol were studied in 7 patients with severe congestive heart failure (IV NYHA) as a result of a low-output-syndrome of varying aetiology (coronary heart disease/cardiomyopathy).	Fenoterol	79-88	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	51-57
6114186-10	1981	The study indicates that the "selective" beta 2-agonist Fenoterol in severe congestive heart failure produces a significant improvement in pump function.	Fenoterol	56-65	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	41-47
6114186-12	1981	Thus Fenoterol seems to be useful in treatment of severe congestive heart failure with elevated TPR.	Fenoterol	5-14	translocated promoter region, nuclear basket protein	Homo sapiens	96-99
6452833-2	1980	EIA was completely blocked by pretreatment with the beta 2-agonist, fenoterol.	Fenoterol	68-77	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	52-58
7409426-4	1980	For protection against paroxysmal supraventricular tachycardia tocolysis with the semiselective beta 2-stimulating compound Fenoterol was started in combination with the beta 1-selective blocking compound Metoprolol.	Fenoterol	124-133	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	96-102
7429136-7	1980	In conclusion the combination of the semiselective beta-2-stimulating compound fenoterol with the beta-1-blocking agent metoprolol is proposed for tocolytic therapy because of less cardial stress but identical tocolytic efficiency as compared with fenoterol-monotherapy.	Fenoterol	79-88	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	51-57
6106579-0	1980	The renin-angiotensin-aldosterone system, antidiuretic hormone levels and water balance under tocolytic therapy with Fenoterol and Verapamil.	Fenoterol	117-126	renin	Homo sapiens	4-9
6102861-1	1980	35 pregnant women were treated with the semiselective beta 2-stimulating compound fenoterol because of threatening premature labor.	Fenoterol	82-91	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	54-60
6102861-3	1980	Metoprolol caused a remarkable and highly significant reduction of the fenoterol-induced cardiac effects: increase of heart rate and augmentation of mean Vcf; the blood pressure was significantly lowered by metoprolol.	Fenoterol	71-80	DiGeorge syndrome chromosome region	Homo sapiens	154-157
6248395-0	1980	Comparison of fenoterol and orciprenaline with regard to broncho-dilating action and beta 2-selectivity.	Fenoterol	14-23	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	85-91
6248395-9	1980	Because finger tremor seems to be due to beta 2-stimulation and palpitation seems to be due to beta 1-stimulation, fenoterol was supposed to be more beta 2-selective than orciprenaline.	Fenoterol	115-124	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	95-101
6248395-9	1980	Because finger tremor seems to be due to beta 2-stimulation and palpitation seems to be due to beta 1-stimulation, fenoterol was supposed to be more beta 2-selective than orciprenaline.	Fenoterol	115-124	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	149-155
6248395-10	1980	In conclusion fenoterol had a high beta 2-selectivity and a powerful and long-lasting broncho-dilating effect compared with orciprenaline.	Fenoterol	14-23	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	35-41
7381123-0	1980	Inhibition of the immediate allergic reaction in the nose by the beta-2 adrenostimulant fenoterol.	Fenoterol	88-97	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	65-71
6165149-1	1980	Fenoterol induced displacements of the fetal oxygen dissociation curve were investigated in animal experiments by determining the oxygen halfsaturation pressure (P 50).	Fenoterol	0-9	Y-box-binding protein 1	Oryctolagus cuniculus	162-166
159182-1	1979	This paper reports a study of the bronchodilator effects of doses of the beta 2 agonist fenoterol and the muscarinic blocker ipratropium suitable for administering in combination as a standard dose of two discharges from a single metered-dose pressurised aerosol.	Fenoterol	88-97	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79
92803-2	1979	Studies on the beta 2-sympathomimetic stimulator fenoterol.	Fenoterol	49-58	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	15-21
92803-4	1979	Fenoterol, a beta 2-sympathomimetic stimulator drug, is shown to be a potent inhibitor of antigen-induced release of histamine.	Fenoterol	0-9	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	13-19
92803-6	1979	Thus, the beta 2-receptor stimulator fenoterol is a valuable drug for treating allergic bronchial asthma since it exhibits a combination of prophylactic and direct therapeutic properties.	Fenoterol	37-46	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	10-16
897365-0	1977	Absorption, distribution and excretion of the tritium-labelled beta2 stimulator fenoterol hydrobromide following aerosol administration and instillation into the bronchial tree.	Fenoterol	80-102	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	63-68
20550-3	1977	The beta2-adrenergic agonists salbutamol, terbutalin, and fenoterol were considerably less effective than the naturally occurring catecholamines.	Fenoterol	58-67	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	4-9
1162529-0	1975	Beta2-selectivity of fenoterol.	Fenoterol	21-30	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5
1013850-0	1976	A comparison of the uterine beta2-adrenoreceptor selectivity of fenoterol, hexoprenaline, ritodrine and salbutamol.	Fenoterol	64-73	adrenoceptor beta 2	Homo sapiens	28-48
1013850-1	1976	A study was undertaken to compare the uterine beta2-adrenoreceptor selectivity of fenoterol, hexoprenaline, ritodrine and salbutamol.	Fenoterol	82-91	adrenoceptor beta 2	Homo sapiens	46-66
240802-9	1975	The parasympatholytic drug, atropine (0.6 mg iv) decreased MTTR"s for at least 3 h. Inhalation of the sympathomimetic drug, Th1165a increased MTTR"s.	Fenoterol	124-131	mitochondrially encoded tRNA arginine	Homo sapiens	59-63
240802-9	1975	The parasympatholytic drug, atropine (0.6 mg iv) decreased MTTR"s for at least 3 h. Inhalation of the sympathomimetic drug, Th1165a increased MTTR"s.	Fenoterol	124-131	mitochondrially encoded tRNA arginine	Homo sapiens	142-146
168693-0	1975	[Influence of fenoterol of cAMP levels and motility on the rat uterus in vitro (author"s transl)].	Fenoterol	14-23	cathelicidin antimicrobial peptide	Rattus norvegicus	27-31
1055321-1	1975	The efficacy of the selective beta 2 sympathomimetic fenoterol (Berotec) in aerosol and tablet forms was studied in 15 subjects with reversible airways obstruction.	Fenoterol	53-62	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	30-36
1055321-1	1975	The efficacy of the selective beta 2 sympathomimetic fenoterol (Berotec) in aerosol and tablet forms was studied in 15 subjects with reversible airways obstruction.	Fenoterol	64-71	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	30-36
168693-1	1975	CAMP levels of isolated rat uteri (2nmol/g wwt) were increased by Fenoterol (10(-4)--1 mug/ml) in a dose dependent manner reaching concentrations of more than 10nmol/g withing 2--5 min.	Fenoterol	66-75	cathelicidin antimicrobial peptide	Rattus norvegicus	0-4
168693-4	1975	However cAMP levels were elevated by Fenoterol in presence of Oxytocin, uterine contractions were not inhibited, i.e. the elevation of cAMP after administration of Fenoterol is correlated with a relaxant effect only in uteri contracting spontaneously.	Fenoterol	37-46	cathelicidin antimicrobial peptide	Rattus norvegicus	8-12
168693-4	1975	However cAMP levels were elevated by Fenoterol in presence of Oxytocin, uterine contractions were not inhibited, i.e. the elevation of cAMP after administration of Fenoterol is correlated with a relaxant effect only in uteri contracting spontaneously.	Fenoterol	164-173	cathelicidin antimicrobial peptide	Rattus norvegicus	8-12
168693-4	1975	However cAMP levels were elevated by Fenoterol in presence of Oxytocin, uterine contractions were not inhibited, i.e. the elevation of cAMP after administration of Fenoterol is correlated with a relaxant effect only in uteri contracting spontaneously.	Fenoterol	164-173	cathelicidin antimicrobial peptide	Rattus norvegicus	135-139
32866780-15	2020	CONCLUSION: We identified 4 already approved drugs (riboflavin, fenoterol, cangrelor and vidarabine) as possible agents for repurposing as inhibitors of S1:ACE2 interaction.	Fenoterol	64-73	angiotensin converting enzyme 2	Homo sapiens	156-160
34040533-7	2021	This was likely due to OCT1 function, as indicated by the fact that IBC correlated with the pharmacokinetics of known OCT1 substrates, like fenoterol, and blood IBC concentrations declined with a 1 h time delay following peak concentrations of the OCT1 substrate sumatriptan.	Fenoterol	140-149	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	23-27
34040533-7	2021	This was likely due to OCT1 function, as indicated by the fact that IBC correlated with the pharmacokinetics of known OCT1 substrates, like fenoterol, and blood IBC concentrations declined with a 1 h time delay following peak concentrations of the OCT1 substrate sumatriptan.	Fenoterol	140-149	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	118-122
34040533-7	2021	This was likely due to OCT1 function, as indicated by the fact that IBC correlated with the pharmacokinetics of known OCT1 substrates, like fenoterol, and blood IBC concentrations declined with a 1 h time delay following peak concentrations of the OCT1 substrate sumatriptan.	Fenoterol	140-149	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	118-122
34025422-2	2021	Common amino acid substitutions in OCT1 were associated with altered pharmacokinetics and efficacy of drugs like sumatriptan and fenoterol.	Fenoterol	129-138	solute carrier family 22 member 1	Homo sapiens	35-39
33711743-7	2021	RESULTS: The results indicated that idarubicin (IDR), a member of the anthracycline antibiotic family, and fenoterol (FNT), a known beta-2 adrenergic agonist drug, tightly bind to the target enzyme and could be used as potential anti-RdRP inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	Fenoterol	107-116	ATPase H+ transporting V0 subunit a2	Homo sapiens	132-138
33711743-7	2021	RESULTS: The results indicated that idarubicin (IDR), a member of the anthracycline antibiotic family, and fenoterol (FNT), a known beta-2 adrenergic agonist drug, tightly bind to the target enzyme and could be used as potential anti-RdRP inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	Fenoterol	107-116	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	234-238
33967805-1	2021	Organic Cation Transporter 1 (OCT1, gene symbol: SLC22A1) is predominately expressed in human liver, localized in the basolateral membrane of hepatocytes and facilitates the uptake of endogenous compounds (e.g. serotonin, acetylcholine, thiamine), and widely prescribed drugs (e.g. metformin, fenoterol, morphine).	Fenoterol	293-302	solute carrier family 22 member 1	Homo sapiens	0-28
33967805-1	2021	Organic Cation Transporter 1 (OCT1, gene symbol: SLC22A1) is predominately expressed in human liver, localized in the basolateral membrane of hepatocytes and facilitates the uptake of endogenous compounds (e.g. serotonin, acetylcholine, thiamine), and widely prescribed drugs (e.g. metformin, fenoterol, morphine).	Fenoterol	293-302	solute carrier family 22 member 1	Homo sapiens	30-34
33967805-1	2021	Organic Cation Transporter 1 (OCT1, gene symbol: SLC22A1) is predominately expressed in human liver, localized in the basolateral membrane of hepatocytes and facilitates the uptake of endogenous compounds (e.g. serotonin, acetylcholine, thiamine), and widely prescribed drugs (e.g. metformin, fenoterol, morphine).	Fenoterol	293-302	solute carrier family 22 member 1	Homo sapiens	49-56
31427432-6	2019	The inhibition potential of CsA towards OCT1 is confirmed by fenoterol hepatocyte uptake experiment.	Fenoterol	61-70	chorionic somatomammotropin hormone 1	Homo sapiens	28-31
32112180-3	2020	The scope of this study was to investigate whether antenatal exposure to the beta2-sympathomimetic fenoterol contributes to the development of ROP.	Fenoterol	99-108	ATPase H+ transporting V0 subunit a2	Homo sapiens	77-82
32115771-8	2020	Their gene expression and intracellular cyclic adenosine monophosphate (cAMP) levels were also investigated in HPDLCs treated with a specific beta2-AR agonist, fenoterol (FEN).	Fenoterol	160-169	adenosine A2a receptor	Rattus norvegicus	142-150
32028718-15	2020	Fenoterol, rolipram, and cilostamide, in AKAP silenced cells, pointed to distinct cAMP compartments.	Fenoterol	0-9	A-kinase anchoring protein 1	Homo sapiens	41-45
32028718-17	2020	AKAP members might define the ability of fenoterol, rolipram, and cilostamide to modulate the EMT process, and they might represent potential relevant targets in the treatment of COPD.	Fenoterol	41-50	A-kinase anchoring protein 1	Homo sapiens	0-4
31771949-8	2020	This aligned with uptake in mouse hepatocytes, in which inhibition of uptake of sumatriptan and fenoterol into mouse hepatocytes by an OCT1 inhibitor was much greater compared to ondansetron and tropisetron.	Fenoterol	96-105	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	135-139
33169817-1	2020	We showed the present data about the efficacy and safety of inhaled short-acting beta2-agonists (SABA), such as salbutamol and fenoterol, in the management of obstructive diseases in children and adults.	Fenoterol	127-136	ATPase H+ transporting V0 subunit a2	Homo sapiens	81-86
31783011-3	2020	OCT1 showed stereoselective uptake with up to 2-fold higher vmax over their corresponding counterpart enantiomers for (R,R)-fenoterol, (R,R)-formoterol, (S)-salbutamol, (S)-acebutolol, and (S)-atenolol.	Fenoterol	124-133	solute carrier family 22 member 1	Homo sapiens	0-4
31783011-7	2020	Other cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-salbutamol.	Fenoterol	166-181	solute carrier family 22 member 1	Homo sapiens	55-59
31783011-7	2020	Other cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-salbutamol.	Fenoterol	166-181	POU class 2 homeobox 2	Homo sapiens	125-129
31783011-7	2020	Other cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-salbutamol.	Fenoterol	166-181	POU class 2 homeobox 2	Homo sapiens	214-218
31783011-7	2020	Other cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-salbutamol.	Fenoterol	166-181	solute carrier family 22 member 3	Homo sapiens	223-227
31783011-7	2020	Other cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-salbutamol.	Fenoterol	172-181	solute carrier family 22 member 1	Homo sapiens	55-59
31783011-7	2020	Other cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-salbutamol.	Fenoterol	172-181	POU class 2 homeobox 2	Homo sapiens	125-129
31783011-7	2020	Other cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-salbutamol.	Fenoterol	172-181	POU class 2 homeobox 2	Homo sapiens	214-218
31783011-7	2020	Other cation transporters showed strong differences to OCT1 in stereoselectivity and transport activity: The closely related OCT2 displayed a 20-fold higher vmax for (S,S)-fenoterol compared to (R,R)-fenoterol and OCT2 and OCT3 showed 3.5-fold and 4.6-fold higher vmax for the pharmacologically active (R)-salbutamol over (S)-salbutamol.	Fenoterol	172-181	solute carrier family 22 member 3	Homo sapiens	223-227
31427432-6	2019	The inhibition potential of CsA towards OCT1 is confirmed by fenoterol hepatocyte uptake experiment.	Fenoterol	61-70	solute carrier family 22 member 1	Homo sapiens	40-44
30933783-1	2019	A simple selective luminescent dependent approach was established for quantitation of two selective beta2 agonists namely; Fenoterol hydrobromide (FEN) and Salmeterol xinafoate (SAL).	Fenoterol	123-145	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	100-105
30933783-1	2019	A simple selective luminescent dependent approach was established for quantitation of two selective beta2 agonists namely; Fenoterol hydrobromide (FEN) and Salmeterol xinafoate (SAL).	Fenoterol	147-150	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	100-105
28791698-2	2018	We studied whether heritable deficiency of the liver organic cation transporter 1 (OCT1), a trait observed in 3% of Europeans and white Americans, affects fenoterol plasma concentrations and toxicity.	Fenoterol	155-164	solute carrier family 22 member 1	Homo sapiens	53-81
30544975-1	2018	The organic cation transporter 1 (OCT1, SLC22A1) is strongly expressed in the human liver and facilitates the hepatic uptake of drugs such as morphine, metformin, tropisetron, sumatriptan and fenoterol and of endogenous substances such as thiamine.	Fenoterol	192-201	solute carrier family 22 member 1	Homo sapiens	4-32
30544975-1	2018	The organic cation transporter 1 (OCT1, SLC22A1) is strongly expressed in the human liver and facilitates the hepatic uptake of drugs such as morphine, metformin, tropisetron, sumatriptan and fenoterol and of endogenous substances such as thiamine.	Fenoterol	192-201	solute carrier family 22 member 1	Homo sapiens	34-38
30544975-1	2018	The organic cation transporter 1 (OCT1, SLC22A1) is strongly expressed in the human liver and facilitates the hepatic uptake of drugs such as morphine, metformin, tropisetron, sumatriptan and fenoterol and of endogenous substances such as thiamine.	Fenoterol	192-201	solute carrier family 22 member 1	Homo sapiens	40-47
29938346-0	2018	Tocolysis with the beta2-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants.	Fenoterol	41-50	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	19-24
29938346-3	2018	The aim of this study was to evaluate whether this observed effect was applicable to other beta2-mimetic tocolytic agents like fenoterol.	Fenoterol	127-136	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	91-96
29722436-5	2018	KEY RESULTS: Under fenoterol stimulation, FRET responses to cilostamide were significantly increased in in vivo, ex vivo PCLS exposed to CS and in human airway smooth muscle cells exposed to CS extract.	Fenoterol	19-28	citrate synthase	Homo sapiens	137-139
29722436-5	2018	KEY RESULTS: Under fenoterol stimulation, FRET responses to cilostamide were significantly increased in in vivo, ex vivo PCLS exposed to CS and in human airway smooth muscle cells exposed to CS extract.	Fenoterol	19-28	citrate synthase	Homo sapiens	191-193
29685885-11	2018	The cAMP efflux triggered by fenoterol/formoterol indicates that the extracellular cAMP-adenosine pathway may play a role in balancing the relaxant effects of beta2-adrenoceptor agonists in airways, which may impact their bronchodilation effects.	Fenoterol	29-38	adrenoceptor beta 2	Rattus norvegicus	159-177
28791698-2	2018	We studied whether heritable deficiency of the liver organic cation transporter 1 (OCT1), a trait observed in 3% of Europeans and white Americans, affects fenoterol plasma concentrations and toxicity.	Fenoterol	155-164	solute carrier family 22 member 1	Homo sapiens	83-87
28791698-3	2018	OCT1 transported fenoterol with high affinity, and OCT1 inhibition in human hepatocytes reduced fenoterol uptake threefold.	Fenoterol	17-26	solute carrier family 22 member 1	Homo sapiens	0-4
28791698-3	2018	OCT1 transported fenoterol with high affinity, and OCT1 inhibition in human hepatocytes reduced fenoterol uptake threefold.	Fenoterol	96-105	solute carrier family 22 member 1	Homo sapiens	0-4
28791698-3	2018	OCT1 transported fenoterol with high affinity, and OCT1 inhibition in human hepatocytes reduced fenoterol uptake threefold.	Fenoterol	96-105	solute carrier family 22 member 1	Homo sapiens	51-55
28791698-4	2018	After administration of 180 microg of fenoterol to 39 healthy individuals, the OCT1-deficient individuals (zero active OCT1 alleles; n = 5) showed 1.9-fold greater systemic fenoterol exposure (P = 4.0 x 10-5 ) and 1.7-fold lower volume of distribution (P = 8.0 x 10-5 ).	Fenoterol	38-47	solute carrier family 22 member 1	Homo sapiens	79-83
28791698-4	2018	After administration of 180 microg of fenoterol to 39 healthy individuals, the OCT1-deficient individuals (zero active OCT1 alleles; n = 5) showed 1.9-fold greater systemic fenoterol exposure (P = 4.0 x 10-5 ) and 1.7-fold lower volume of distribution (P = 8.0 x 10-5 ).	Fenoterol	173-182	solute carrier family 22 member 1	Homo sapiens	79-83
28791698-6	2018	In conclusion, heritable OCT1 deficiency significantly increases plasma concentrations of fenoterol and may be an important factor underlying the excess mortality associated with fenoterol.	Fenoterol	90-99	solute carrier family 22 member 1	Homo sapiens	25-29
28791698-6	2018	In conclusion, heritable OCT1 deficiency significantly increases plasma concentrations of fenoterol and may be an important factor underlying the excess mortality associated with fenoterol.	Fenoterol	179-188	solute carrier family 22 member 1	Homo sapiens	25-29
27170493-5	2017	Influence of 1mM MbetaCD on the fenoterol-driven changes in both contractility and NO level was strongly attenuated by inhibition of Gi-protein (pertussis toxin), Akt (Akt 1/2 kinase inhibitor) or NO-synthase (L-NAME).	Fenoterol	32-41	thymoma viral proto-oncogene 1	Mus musculus	163-166
29210147-9	2018	A reduced risk of MS was observed with exposure to the beta2-adrenergic agonist fenoterol (adj.OR = 0.58;95%CI:0.45-0.76), and the sedating histamine 1-receptor antagonists (adj.OR = 0.2;95%CI:0.1-0.8), but not the non-sedating equivalent (adj.OR = 0.8;95%CI:0.4-1.6).	Fenoterol	80-89	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	55-60
28888956-10	2017	Along similar lines, enrichment of plasma membranes with cholesterol reduced the stimulatory effect of 5alphaCh3 on beta2-adrenoceptor-evoked NO production, but not on the Ca2+-transient amplitude, leading to an elevation of the positive inotropic response to fenoterol.	Fenoterol	260-269	adrenergic receptor, beta 2	Mus musculus	116-134
28888956-2	2017	We have investigated the mechanism by which the cholesterol metabolite 5alpha-cholestan-3-one (5alphaCh3) modulates inotropic effect of beta2-adrenoceptor agonist fenoterol.	Fenoterol	163-172	adrenergic receptor, beta 2	Mus musculus	136-154
28888956-8	2017	Under conditions of a pharmacological inhibition of Gi-protein/Akt/NO synthase/protein kinase G signaling, 5alphaCh3 augmented the inotropic effect of fenoterol.	Fenoterol	151-160	thymoma viral proto-oncogene 1	Mus musculus	63-66
28603032-5	2017	Epinephrine effects towards transporter mRNA expression in human hepatocytes were next shown to be correlated to those of the selective beta2-adrenoreceptor (ADR) agonist fenoterol, of the adenylate cyclase activator forskolin and of the cAMP analogue 8-bromo-cAMP.	Fenoterol	171-180	adrenoceptor beta 2	Homo sapiens	136-156
27170493-5	2017	Influence of 1mM MbetaCD on the fenoterol-driven changes in both contractility and NO level was strongly attenuated by inhibition of Gi-protein (pertussis toxin), Akt (Akt 1/2 kinase inhibitor) or NO-synthase (L-NAME).	Fenoterol	32-41	thymoma viral proto-oncogene 1	Mus musculus	168-171
28338133-3	2017	In particular, many experimental and theoretical studies confirmed that stereoisomers of an important beta2-AR agonist, fenoterol, are associated with diverse mechanisms of binding and activation of beta2-AR.	Fenoterol	120-129	adrenoceptor beta 2	Homo sapiens	102-110
28338133-3	2017	In particular, many experimental and theoretical studies confirmed that stereoisomers of an important beta2-AR agonist, fenoterol, are associated with diverse mechanisms of binding and activation of beta2-AR.	Fenoterol	120-129	adrenoceptor beta 2	Homo sapiens	199-207
28338133-4	2017	The objective of the present study was to explore the stereoselective binding of fenoterol to beta2-AR through the application of an advanced computational methodology based on enhanced-sampling molecular dynamics simulations and potentials of interactions tailored to investigate the stereorecognition effects.	Fenoterol	81-90	adrenoceptor beta 2	Homo sapiens	94-102
27657826-0	2016	Anti-inflammatory activities of fenoterol through beta-arrestin-2 and inhibition of AMPK and NF-kappaB activation in AICAR-induced THP-1 cells.	Fenoterol	32-41	arrestin beta 2	Homo sapiens	50-65
27657826-0	2016	Anti-inflammatory activities of fenoterol through beta-arrestin-2 and inhibition of AMPK and NF-kappaB activation in AICAR-induced THP-1 cells.	Fenoterol	32-41	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	84-88
27657826-2	2016	We reported that fenoterol, a beta2-adrenergic receptor (beta2-AR) agonist, inhibited lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells, a monocytic cell line in previous studies.	Fenoterol	17-26	adrenoceptor beta 2	Homo sapiens	57-65
27657826-2	2016	We reported that fenoterol, a beta2-adrenergic receptor (beta2-AR) agonist, inhibited lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells, a monocytic cell line in previous studies.	Fenoterol	17-26	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	119-123
27657826-5	2016	In this study, we explored the mechanism of beta2-AR stimulation with fenoterol in AICAR-induced inflammatory cytokine secretion in THP-1 cells.	Fenoterol	70-79	adrenoceptor beta 2	Homo sapiens	44-52
27657826-7	2016	AICAR-induced AMPK activation, NF-kappaB activation and tumor necrosis factor (TNF)-alpha release were reduced by fenoterol.	Fenoterol	114-123	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	14-18
27657826-7	2016	AICAR-induced AMPK activation, NF-kappaB activation and tumor necrosis factor (TNF)-alpha release were reduced by fenoterol.	Fenoterol	114-123	nuclear factor kappa B subunit 1	Homo sapiens	31-40
27657826-7	2016	AICAR-induced AMPK activation, NF-kappaB activation and tumor necrosis factor (TNF)-alpha release were reduced by fenoterol.	Fenoterol	114-123	tumor necrosis factor	Homo sapiens	56-89
27657826-8	2016	In addition, siRNA-mediated knockdown of beta-arrestin-2 abolished fenoterol"s inhibition of AICAR-induced AMPK activation and TNF-alpha release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol in AICAR-treated THP-1 cells.	Fenoterol	67-76	arrestin beta 2	Homo sapiens	41-56
27657826-8	2016	In addition, siRNA-mediated knockdown of beta-arrestin-2 abolished fenoterol"s inhibition of AICAR-induced AMPK activation and TNF-alpha release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol in AICAR-treated THP-1 cells.	Fenoterol	67-76	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	107-111
27657826-8	2016	In addition, siRNA-mediated knockdown of beta-arrestin-2 abolished fenoterol"s inhibition of AICAR-induced AMPK activation and TNF-alpha release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol in AICAR-treated THP-1 cells.	Fenoterol	67-76	tumor necrosis factor	Homo sapiens	127-136
27657826-8	2016	In addition, siRNA-mediated knockdown of beta-arrestin-2 abolished fenoterol"s inhibition of AICAR-induced AMPK activation and TNF-alpha release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol in AICAR-treated THP-1 cells.	Fenoterol	67-76	arrestin beta 2	Homo sapiens	151-166
27657826-8	2016	In addition, siRNA-mediated knockdown of beta-arrestin-2 abolished fenoterol"s inhibition of AICAR-induced AMPK activation and TNF-alpha release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol in AICAR-treated THP-1 cells.	Fenoterol	209-218	arrestin beta 2	Homo sapiens	41-56
27657826-8	2016	In addition, siRNA-mediated knockdown of beta-arrestin-2 abolished fenoterol"s inhibition of AICAR-induced AMPK activation and TNF-alpha release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol in AICAR-treated THP-1 cells.	Fenoterol	209-218	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	107-111
27657826-8	2016	In addition, siRNA-mediated knockdown of beta-arrestin-2 abolished fenoterol"s inhibition of AICAR-induced AMPK activation and TNF-alpha release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol in AICAR-treated THP-1 cells.	Fenoterol	209-218	tumor necrosis factor	Homo sapiens	127-136
27657826-8	2016	In addition, siRNA-mediated knockdown of beta-arrestin-2 abolished fenoterol"s inhibition of AICAR-induced AMPK activation and TNF-alpha release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol in AICAR-treated THP-1 cells.	Fenoterol	209-218	arrestin beta 2	Homo sapiens	151-166
27657826-10	2016	These data suggested that fenoterol inhibited AICAR-induced AMPK activation and TNF-alpha release through beta-arrestin-2 in THP-1 cells.	Fenoterol	26-35	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	60-64
27657826-10	2016	These data suggested that fenoterol inhibited AICAR-induced AMPK activation and TNF-alpha release through beta-arrestin-2 in THP-1 cells.	Fenoterol	26-35	tumor necrosis factor	Homo sapiens	80-89
27657826-10	2016	These data suggested that fenoterol inhibited AICAR-induced AMPK activation and TNF-alpha release through beta-arrestin-2 in THP-1 cells.	Fenoterol	26-35	arrestin beta 2	Homo sapiens	106-121
26604244-9	2016	Interestingly, ECs expressing the betaARKct fenoterol, a beta2AR-agonist, induced enhanced beta2AR proangiogenic signaling and increased EC function.	Fenoterol	44-53	adrenoceptor beta 2	Rattus norvegicus	57-64
26604244-9	2016	Interestingly, ECs expressing the betaARKct fenoterol, a beta2AR-agonist, induced enhanced beta2AR proangiogenic signaling and increased EC function.	Fenoterol	44-53	adrenoceptor beta 2	Rattus norvegicus	91-98
25930996-2	2015	We reported that fenoterol, a beta2-adrenergic receptor (beta2-AR) agonist, had anti-inflammatory effects in THP-1 cells, a monocytic cell line.	Fenoterol	17-26	adrenoceptor beta 2	Homo sapiens	57-65
27174812-7	2016	Results from Glide Docking showed that Fenoterol had highest affinity for mutated receptor and stood as second best (after Salbutamol) high affinity agonist for wild receptor among the established beta2 agonists.	Fenoterol	39-48	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	197-202
25930996-0	2015	Fenoterol inhibits LPS-induced AMPK activation and inflammatory cytokine production through beta-arrestin-2 in THP-1 cell line.	Fenoterol	0-9	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	31-35
26297975-1	2015	Fenoterol, a beta2-adrenoceptor agonist, has anti-apoptotic action in cardiomyocytes and induces a specific pattern of downstream signaling.	Fenoterol	0-9	adrenergic receptor, beta 2	Mus musculus	13-31
26297975-10	2015	We suggest that stimulation of beta2-adrenoceptor with fenoterol causes the activation of NADPH-oxidase and after the agonist removal extracellularly generated ROS penetrates into the cell, increasing the atrial contractions probably via Ca2+ channels.	Fenoterol	55-64	adrenergic receptor, beta 2	Mus musculus	31-49
25930996-0	2015	Fenoterol inhibits LPS-induced AMPK activation and inflammatory cytokine production through beta-arrestin-2 in THP-1 cell line.	Fenoterol	0-9	arrestin beta 2	Homo sapiens	92-107
25930996-4	2015	In this study, we explored the mechanism of beta2-AR stimulation with fenoterol in a lipopolysaccharide (LPS)-induced inflammatory cytokine secretion in THP-1 cells.	Fenoterol	70-79	adrenoceptor beta 2	Homo sapiens	44-52
25930996-6	2015	LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release were reduced with fenoterol pretreatment of THP-1 cells.	Fenoterol	87-96	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	12-16
25930996-6	2015	LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release were reduced with fenoterol pretreatment of THP-1 cells.	Fenoterol	87-96	interleukin 1 beta	Homo sapiens	32-49
25930996-6	2015	LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release were reduced with fenoterol pretreatment of THP-1 cells.	Fenoterol	87-96	interleukin 1 beta	Homo sapiens	51-59
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	49-58	arrestin beta 2	Homo sapiens	19-34
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	49-58	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	85-89
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	49-58	interleukin 1 beta	Homo sapiens	105-122
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	49-58	interleukin 1 beta	Homo sapiens	124-132
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	49-58	arrestin beta 2	Homo sapiens	148-163
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	206-215	arrestin beta 2	Homo sapiens	19-34
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	206-215	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	85-89
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	206-215	interleukin 1 beta	Homo sapiens	105-122
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	206-215	interleukin 1 beta	Homo sapiens	124-132
25930996-7	2015	SiRNA knockdown of beta-arrestin-2 abolished the fenoterol inhibition of LPS-induced AMPK activation and interleukin 1beta (IL-1beta) release, thus beta-arrestin-2 mediated the anti-inflammatory effects of fenoterol on LPS-treated THP-1 cells.	Fenoterol	206-215	arrestin beta 2	Homo sapiens	148-163
25930996-9	2015	These results suggested the beta2-AR agonist fenoterol inhibited LPS-induced AMPK activation and IL-1beta release via beta-arrestin-2 in THP-1 cells.	Fenoterol	45-54	adrenoceptor beta 2	Homo sapiens	28-36
25930996-9	2015	These results suggested the beta2-AR agonist fenoterol inhibited LPS-induced AMPK activation and IL-1beta release via beta-arrestin-2 in THP-1 cells.	Fenoterol	45-54	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	77-81
25930996-9	2015	These results suggested the beta2-AR agonist fenoterol inhibited LPS-induced AMPK activation and IL-1beta release via beta-arrestin-2 in THP-1 cells.	Fenoterol	45-54	interleukin 1 beta	Homo sapiens	97-105
25930996-9	2015	These results suggested the beta2-AR agonist fenoterol inhibited LPS-induced AMPK activation and IL-1beta release via beta-arrestin-2 in THP-1 cells.	Fenoterol	45-54	arrestin beta 2	Homo sapiens	118-133